{"transactions":[{"id":678608,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":20798,"kind":"person","name":"LYNCH TIMOTHY P","position":1,"cik":"0001270925","reported_name":"LYNCH TIMOTHY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2026-08-21T23:41:07.000Z","date":"2026-08-19","kind":"purchase","planned":false,"acquired":true,"shares":1150000,"price":0.2117,"value":243455.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $0.1975 to $0.2164 inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":6500000,"source":{"system":"sec-edgar","filing":"0000935836-26-000440","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270925/000093583626000440/form4.xml","form_type":"4"}},{"id":730391,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36311,"kind":"person","name":"Thunen Shelley B","position":1,"cik":"0001297491","reported_name":"Thunen Shelley B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-06-22T22:22:10.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":222684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\") granted on June 17, 2026 (the \"Grant Date\").  The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\") granted on June 17, 2026 (the \"Grant Date\").  The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date."}],"balance_after":258705,"source":{"system":"sec-edgar","filing":"0001104659-26-076515","document":"tm2618486-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1297491/000110465926076515/tm2618486-5_4seq1.xml","form_type":"4"}},{"id":730879,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36462,"kind":"person","name":"PALMISANO ROBERT J","position":1,"cik":"0001138646","reported_name":"PALMISANO ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-06-22T22:20:49.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":222684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\") granted on June 17, 2026 (the \"Grant Date\"). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\") granted on June 17, 2026 (the \"Grant Date\"). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date."}],"balance_after":258705,"source":{"system":"sec-edgar","filing":"0001104659-26-076513","document":"tm2618486-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138646/000110465926076513/tm2618486-4_4seq1.xml","form_type":"4"}},{"id":731100,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36519,"kind":"person","name":"Forth Marc","position":1,"cik":"0001816988","reported_name":"Forth Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-06-22T22:19:13.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":222684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\") granted on June 17, 2026 (the \"Grant Date\"). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the\nGrant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\") granted on June 17, 2026 (the \"Grant Date\"). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the\nGrant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date."}],"balance_after":973231,"source":{"system":"sec-edgar","filing":"0001104659-26-076511","document":"tm2618486-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816988/000110465926076511/tm2618486-3_4seq1.xml","form_type":"4"}},{"id":730180,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36267,"kind":"person","name":"FISCHER JOST","position":1,"cik":"0001366841","reported_name":"FISCHER JOST","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-06-22T22:17:44.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":222684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\") granted on June 17, 2026 (the \"Grant Date\").  The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\") granted on June 17, 2026 (the \"Grant Date\").  The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date."}],"balance_after":489469,"source":{"system":"sec-edgar","filing":"0001104659-26-076510","document":"tm2618486-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366841/000110465926076510/tm2618486-2_4seq1.xml","form_type":"4"}},{"id":730165,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36264,"kind":"person","name":"Carter Eric G","position":1,"cik":"0001387660","reported_name":"Carter Eric G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-06-22T22:16:10.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":222684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\") granted on June 17, 2026 (the \"Grant Date\").  The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\") granted on June 17, 2026 (the \"Grant Date\").  The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date."}],"balance_after":258705,"source":{"system":"sec-edgar","filing":"0001104659-26-076509","document":"tm2618486-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1387660/000110465926076509/tm2618486-1_4seq1.xml","form_type":"4"}},{"id":816264,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":53826,"kind":"person","name":"Bencich John","position":1,"cik":"0001477056","reported_name":"Bencich John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Common Stock","published_at":"2026-04-03T22:22:30.000Z","date":"2026-04-02","kind":"grant","planned":false,"acquired":true,"shares":754717,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an award of restricted stock units granted on April 1, 2026 (the \"Grant Date\"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units granted on April 1, 2026 (the \"Grant Date\"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date."}],"balance_after":754717,"source":{"system":"sec-edgar","filing":"0001104659-26-039697","document":"tm2611116-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477056/000110465926039697/tm2611116-2_4seq1.xml","form_type":"4"}},{"id":848994,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":61532,"kind":"person","name":"Oh Chad","position":1,"cik":"0001882166","reported_name":"Oh Chad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Class A Common Stock","published_at":"2026-03-11T20:13:33.000Z","date":"2026-03-04","kind":"grant","planned":false,"acquired":true,"shares":1316872,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the \"Grant Date\") that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the \"Grant Date\") that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025."}],"balance_after":2183436,"source":{"system":"sec-edgar","filing":"0001104659-26-026550","document":"tm268617-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882166/000110465926026550/tm268617-1_4seq1.xml","form_type":"4"}},{"id":848993,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":61532,"kind":"person","name":"Oh Chad","position":1,"cik":"0001882166","reported_name":"Oh Chad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Class A Common Stock","published_at":"2026-03-11T20:13:33.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":862500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an award of restricted stock units granted on February 17, 2026 (the \"Grant Date\"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units granted on February 17, 2026 (the \"Grant Date\"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date."}],"balance_after":866564,"source":{"system":"sec-edgar","filing":"0001104659-26-026550","document":"tm268617-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882166/000110465926026550/tm268617-1_4seq1.xml","form_type":"4"}},{"id":857667,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62488,"kind":"person","name":"Wilson Alexander Blair","position":1,"cik":"0001979602","reported_name":"Wilson Alexander Blair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO, CSO, and Corp Secretary"}}],"security":"Class A Common Stock","published_at":"2026-03-05T23:07:56.000Z","date":"2026-03-04","kind":"grant","planned":false,"acquired":true,"shares":1316872,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the \"Grant Date\") that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the \"Grant Date\") that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025."}],"balance_after":2183005,"source":{"system":"sec-edgar","filing":"0001104659-26-024233","document":"tm268148-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465926024233/tm268148-2_4seq1.xml","form_type":"4"}},{"id":857666,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62488,"kind":"person","name":"Wilson Alexander Blair","position":1,"cik":"0001979602","reported_name":"Wilson Alexander Blair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO, CSO, and Corp Secretary"}}],"security":"Class A Common Stock","published_at":"2026-03-05T23:07:56.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":862500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an award of restricted stock units granted on February 17, 2026 (the \"Grant Date\"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units granted on February 17, 2026 (the \"Grant Date\"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date."}],"balance_after":866133,"source":{"system":"sec-edgar","filing":"0001104659-26-024233","document":"tm268148-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465926024233/tm268148-2_4seq1.xml","form_type":"4"}},{"id":858978,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62603,"kind":"person","name":"Sy Jennifer","position":1,"cik":"0002023998","reported_name":"Sy Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Class A Common Stock","published_at":"2026-03-05T18:06:25.000Z","date":"2026-03-04","kind":"grant","planned":false,"acquired":true,"shares":925925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the \"Grant Date\") that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the \"Grant Date\") that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025."}],"balance_after":1501176,"source":{"system":"sec-edgar","filing":"0001104659-26-024231","document":"tm268148-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2023998/000110465926024231/tm268148-1_4seq1.xml","form_type":"4"}},{"id":858977,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62603,"kind":"person","name":"Sy Jennifer","position":1,"cik":"0002023998","reported_name":"Sy Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Class A Common Stock","published_at":"2026-03-05T18:06:25.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":575000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an award of restricted stock units granted on February 17, 2026 (the \"Grant Date\"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units granted on February 17, 2026 (the \"Grant Date\"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date."}],"balance_after":575251,"source":{"system":"sec-edgar","filing":"0001104659-26-024231","document":"tm268148-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2023998/000110465926024231/tm268148-1_4seq1.xml","form_type":"4"}},{"id":892355,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":65606,"kind":"person","name":"Bancroft Robert E.","position":1,"cik":"0002066370","reported_name":"Bancroft Robert E.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Class A Common Stock","published_at":"2026-02-20T01:40:27.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":3000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an award of restricted stock units granted on February 17, 2026 (the \"Grant Date\"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units granted on February 17, 2026 (the \"Grant Date\"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date."}],"balance_after":3177103,"source":{"system":"sec-edgar","filing":"0001104659-26-017726","document":"tm266901-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465926017726/tm266901-1_4seq1.xml","form_type":"4"}},{"id":1135071,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36311,"kind":"person","name":"Thunen Shelley B","position":1,"cik":"0001297491","reported_name":"Thunen Shelley B","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2025-05-23T21:04:47.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":308641,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") will be settled in cash based on the fair market value of the Issuer's Class A Common Stock on the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the RSUs shall vest in full on the one year anniversary of May 21, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"100% of the RSUs shall vest in full on the one year anniversary of May 21, 2025."}],"balance_after":308641,"derivative":{"underlying":"Class A Common Stock","underlying_shares":308641},"source":{"system":"sec-edgar","filing":"0001610717-25-000141","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1297491/000161071725000141/form4.xml","form_type":"4"}},{"id":1134665,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62488,"kind":"person","name":"Wilson Alexander Blair","position":1,"cik":"0001979602","reported_name":"Wilson Alexander Blair","relationship":{"officer":true,"officer_title":"Exec VP, CLO & Corp Secretary"}}],"security":"Restricted Stock Units","published_at":"2025-05-23T20:57:12.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":1316872,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") will be settled in cash based on the fair market value of the Issuer's Class A Common Stock on the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the RSUs shall vest on each anniversary of May 21, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"25% of the RSUs shall vest on each anniversary of May 21, 2025."}],"balance_after":1316872,"derivative":{"underlying":"Class A Common Stock","underlying_shares":1316872},"source":{"system":"sec-edgar","filing":"0001610717-25-000137","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000161071725000137/form4.xml","form_type":"4"}},{"id":1136066,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36519,"kind":"person","name":"Forth Marc","position":1,"cik":"0001816988","reported_name":"Forth Marc","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2025-05-23T20:54:56.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":370370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") will be settled in cash based on the fair market value of the Issuer's Class A Common Stock on the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/3rd of the RSUs shall vest on each anniversary of May 21, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"1/3rd of the RSUs shall vest on each anniversary of May 21, 2025."}],"balance_after":370370,"derivative":{"underlying":"Class A Common Stock","underlying_shares":370370},"source":{"system":"sec-edgar","filing":"0001610717-25-000134","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816988/000161071725000134/form4.xml","form_type":"4"}},{"id":1135750,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36462,"kind":"person","name":"PALMISANO ROBERT J","position":1,"cik":"0001138646","reported_name":"PALMISANO ROBERT J","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2025-05-23T20:51:31.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":308641,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") will be settled in cash based on the fair market value of the Issuer's Class A Common Stock on the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the RSUs shall vest in full on the one year anniversary of May 21, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"100% of the RSUs shall vest in full on the one year anniversary of May 21, 2025."}],"balance_after":308641,"derivative":{"underlying":"Class A Common Stock","underlying_shares":308641},"source":{"system":"sec-edgar","filing":"0001610717-25-000132","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138646/000161071725000132/form4.xml","form_type":"4"}},{"id":1134860,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36264,"kind":"person","name":"Carter Eric G","position":1,"cik":"0001387660","reported_name":"Carter Eric G","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2025-05-23T20:50:53.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":308641,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") will be settled in cash based on the fair market value of the Issuer's Class A Common Stock on the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the RSUs shall vest in full on the one year anniversary of May 21, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"100% of the RSUs shall vest in full on the one year anniversary of May 21, 2025."}],"balance_after":308641,"derivative":{"underlying":"Class A Common Stock","underlying_shares":308641},"source":{"system":"sec-edgar","filing":"0001610717-25-000131","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1387660/000161071725000131/form4.xml","form_type":"4"}},{"id":1134881,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36267,"kind":"person","name":"FISCHER JOST","position":1,"cik":"0001366841","reported_name":"FISCHER JOST","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2025-05-23T20:50:05.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":308641,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") will be settled in cash based on the fair market value of the Issuer's Class A Common Stock on the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the RSUs shall vest in full on the one year anniversary of May 21, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"100% of the RSUs shall vest in full on the one year anniversary of May 21, 2025."}],"balance_after":308641,"derivative":{"underlying":"Class A Common Stock","underlying_shares":308641},"source":{"system":"sec-edgar","filing":"0001610717-25-000130","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366841/000161071725000130/form4.xml","form_type":"4"}},{"id":1134880,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36267,"kind":"person","name":"FISCHER JOST","position":1,"cik":"0001366841","reported_name":"FISCHER JOST","relationship":{"director":true}}],"security":"Class A Common Stock","published_at":"2025-05-23T20:46:16.000Z","date":"2025-05-21","kind":"purchase","planned":false,"acquired":true,"shares":60000,"price":0.4875,"value":29250.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades in prices ranging from $0.4659 to $0.4999, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote."}],"balance_after":266785,"source":{"system":"sec-edgar","filing":"0001610717-25-000129","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366841/000161071725000129/form4.xml","form_type":"4"}},{"id":1135585,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":61532,"kind":"person","name":"Oh Chad","position":1,"cik":"0001882166","reported_name":"Oh Chad","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2025-05-23T16:56:33.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":1316872,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") will be settled in cash based on the fair market value of the Issuer's Class A Common Stock on the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the RSUs shall vest on each anniversary of May 21, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"25% of the RSUs shall vest on each anniversary of May 21, 2025."}],"balance_after":1316872,"derivative":{"underlying":"Class A Common Stock","underlying_shares":1316872},"source":{"system":"sec-edgar","filing":"0001610717-25-000136","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882166/000161071725000136/form4.xml","form_type":"4"}},{"id":1135664,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62603,"kind":"person","name":"Sy Jennifer","position":1,"cik":"0002023998","reported_name":"Sy Jennifer","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Restricted Stock Units","published_at":"2025-05-23T16:55:36.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":925925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") will be settled in cash based on the fair market value of the Issuer's Class A Common Stock on the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the RSUs shall vest on each anniversary of May 21, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"25% of the RSUs shall vest on each anniversary of May 21, 2025."}],"balance_after":925925,"derivative":{"underlying":"Class A Common Stock","underlying_shares":925925},"source":{"system":"sec-edgar","filing":"0001610717-25-000135","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2023998/000161071725000135/form4.xml","form_type":"4"}},{"id":1138776,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36267,"kind":"person","name":"FISCHER JOST","position":1,"cik":"0001366841","reported_name":"FISCHER JOST","relationship":{"director":true}}],"security":"Class A Common Stock","published_at":"2025-05-21T20:50:20.000Z","date":"2025-05-20","kind":"purchase","planned":false,"acquired":true,"shares":60000,"price":0.506,"value":30360.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades in prices ranging from $0.50 to $0.5132, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote."}],"balance_after":206785,"source":{"system":"sec-edgar","filing":"0001610717-25-000124","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366841/000161071725000124/form4.xml","form_type":"4"}},{"id":1138775,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36267,"kind":"person","name":"FISCHER JOST","position":1,"cik":"0001366841","reported_name":"FISCHER JOST","relationship":{"director":true}}],"security":"Class A Common Stock","published_at":"2025-05-21T20:50:20.000Z","date":"2025-05-19","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":0.4988,"value":24940.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades in prices ranging from $0.4844 to $0.51, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote."}],"balance_after":146785,"source":{"system":"sec-edgar","filing":"0001610717-25-000124","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366841/000161071725000124/form4.xml","form_type":"4"}},{"id":1144609,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":65606,"kind":"person","name":"Bancroft Robert E.","position":1,"cik":"0002066370","reported_name":"Bancroft Robert E.","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Class A Common Stock","published_at":"2025-05-16T20:17:08.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":177103,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Class A Common Stock for each RSU upon vesting. 25% of the RSUs shall vest on each anniversary of April 29, 2025."}],"balance_after":177103,"source":{"system":"sec-edgar","filing":"0001610717-25-000120","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000161071725000120/form4.xml","form_type":"4"}},{"id":1162238,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":65606,"kind":"person","name":"Bancroft Robert E.","position":1,"cik":"0002066370","reported_name":"Bancroft Robert E.","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Stock Option","published_at":"2025-05-01T20:50:50.000Z","date":"2025-04-29","kind":"grant","planned":false,"acquired":true,"shares":59034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on each anniversary measured from April 29, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":59034,"derivative":{"exercise_price":0.41,"expiration_date":"2035-04-29","underlying":"Class A Common Stock","underlying_shares":59034},"source":{"system":"sec-edgar","filing":"0001610717-25-000111","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000161071725000111/form4.xml","form_type":"4"}},{"id":1411055,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36462,"kind":"person","name":"PALMISANO ROBERT J","position":1,"cik":"0001138646","reported_name":"PALMISANO ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-09-11T01:04:24.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":36021,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units granted on August 31, 2024 (the \"Grant Date\"), which vests in full on the second anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":36021,"source":{"system":"sec-edgar","filing":"0001104659-24-098707","document":"tm2423757-1_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138646/000110465924098707/tm2423757-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-09-04"}},{"id":1416695,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36519,"kind":"person","name":"Forth Marc","position":1,"cik":"0001816988","reported_name":"Forth Marc","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECTUIVE OFFICER"}}],"security":"Stock Option","published_at":"2024-09-05T01:59:14.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":1256062,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents an award of stock options granted on August 31, 2024 (the \"Grant Date\"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents an award of stock options granted on August 31, 2024 (the \"Grant Date\"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":1256062,"derivative":{"exercise_price":0.83,"expiration_date":"2034-08-30","underlying":"Class A Common Stock","underlying_shares":1256062},"source":{"system":"sec-edgar","filing":"0001104659-24-097067","document":"tm2423415-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816988/000110465924097067/tm2423415-3_4seq1.xml","form_type":"4"}},{"id":1416694,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36519,"kind":"person","name":"Forth Marc","position":1,"cik":"0001816988","reported_name":"Forth Marc","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECTUIVE OFFICER"}}],"security":"Class A Common Stock","published_at":"2024-09-05T01:59:14.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":470692,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units granted on August 31, 2024 (the \"Grant Date\"), which vests in full on the second anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an award of restricted stock units (\"RSUs\") in the amount of 279,855 previously granted on April 26, 2023, which were previously reported on July 24, 2023 as derivative securities in Table II due to a clerical error, and which are now being reported as common stock in Table I.  The vesting terms for the RSUs have not changed from what was previously reported on July 24, 2023."}],"balance_after":750547,"source":{"system":"sec-edgar","filing":"0001104659-24-097067","document":"tm2423415-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816988/000110465924097067/tm2423415-3_4seq1.xml","form_type":"4"}},{"id":1415023,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62488,"kind":"person","name":"Wilson Alexander Blair","position":1,"cik":"0001979602","reported_name":"Wilson Alexander Blair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EXEC VP, CLO & CORP SECRETARY"}}],"security":"Stock Option","published_at":"2024-09-05T01:58:43.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":480631,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents an award of stock options granted on August 31, 2024 (the \"Grant Date\"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents an award of stock options granted on August 31, 2024 (the \"Grant Date\"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":480631,"derivative":{"exercise_price":0.83,"expiration_date":"2034-08-30","underlying":"Class A Common Stock","underlying_shares":480631},"source":{"system":"sec-edgar","filing":"0001104659-24-097066","document":"tm2423415-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465924097066/tm2423415-7_4seq1.xml","form_type":"4"}},{"id":1415022,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62488,"kind":"person","name":"Wilson Alexander Blair","position":1,"cik":"0001979602","reported_name":"Wilson Alexander Blair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EXEC VP, CLO & CORP SECRETARY"}}],"security":"Class A Common Stock","published_at":"2024-09-05T01:58:43.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":180110,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units granted on August 31, 2024 (the \"Grant Date\"), which vests in full on the second anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an award of restricted stock units (\"RSUs\") in the amount of 81,428 previously granted on April 26, 2023, which were previously reported on July 24, 2023 as derivative securities in Table II due to a clerical error, and which are now being reported as common stock in Table I. The vesting terms for the RSUs have not changed from what was previously reported on July 24, 2023."}],"balance_after":261538,"source":{"system":"sec-edgar","filing":"0001104659-24-097066","document":"tm2423415-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465924097066/tm2423415-7_4seq1.xml","form_type":"4"}},{"id":1415351,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36267,"kind":"person","name":"FISCHER JOST","position":1,"cik":"0001366841","reported_name":"FISCHER JOST","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-09-05T01:58:12.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":96210,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents an award of stock options granted on August 31, 2024 (the \"Grant Date\"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents an award of stock options granted on August 31, 2024 (the \"Grant Date\"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":96210,"derivative":{"exercise_price":0.83,"expiration_date":"2034-08-30","underlying":"Class A Common Stock","underlying_shares":96210},"source":{"system":"sec-edgar","filing":"0001104659-24-097065","document":"tm2423415-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366841/000110465924097065/tm2423415-2_4seq1.xml","form_type":"4"}},{"id":1415350,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36267,"kind":"person","name":"FISCHER JOST","position":1,"cik":"0001366841","reported_name":"FISCHER JOST","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-09-05T01:58:12.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":36021,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units granted on August 31, 2024 (the \"Grant Date\"), which vests in full on the second anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes multiple awards of restricted stock units (\"RSUs\") in the amounts of 19,286, 6,289, and 35,189 previously granted on April 26, 2023, which were previously reported on July 24, 2023 as derivative securities in Table II due to a clerical error, and which are now being reported as common stock in Table I. The vesting terms for the RSUs have not changed from what was previously reported on July 24, 2023."}],"balance_after":96785,"source":{"system":"sec-edgar","filing":"0001104659-24-097065","document":"tm2423415-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366841/000110465924097065/tm2423415-2_4seq1.xml","form_type":"4"}},{"id":1415331,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36264,"kind":"person","name":"Carter Eric G","position":1,"cik":"0001387660","reported_name":"Carter Eric G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-09-05T01:52:57.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":96210,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents an award of stock options granted on August 31, 2024 (the \"Grant Date\"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents an award of stock options granted on August 31, 2024 (the \"Grant Date\"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":96210,"derivative":{"exercise_price":0.83,"expiration_date":"2034-08-30","underlying":"Class A Common Stock","underlying_shares":96210},"source":{"system":"sec-edgar","filing":"0001104659-24-097061","document":"tm2423415-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1387660/000110465924097061/tm2423415-1_4seq1.xml","form_type":"4"}},{"id":1415330,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36264,"kind":"person","name":"Carter Eric G","position":1,"cik":"0001387660","reported_name":"Carter Eric G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-09-05T01:52:57.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":36021,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units granted on August 31, 2024 (the \"Grant Date\"), which vests in full on the second anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":36021,"source":{"system":"sec-edgar","filing":"0001104659-24-097061","document":"tm2423415-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1387660/000110465924097061/tm2423415-1_4seq1.xml","form_type":"4"}},{"id":1415431,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36311,"kind":"person","name":"Thunen Shelley B","position":1,"cik":"0001297491","reported_name":"Thunen Shelley B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-09-05T01:51:54.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":96210,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents an award of stock options granted on August 31, 2024 (the \"Grant Date\"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents an award of stock options granted on August 31, 2024 (the \"Grant Date\"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":96210,"derivative":{"exercise_price":0.83,"expiration_date":"2034-08-30","underlying":"Class A Common Stock","underlying_shares":96210},"source":{"system":"sec-edgar","filing":"0001104659-24-097060","document":"tm2423415-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1297491/000110465924097060/tm2423415-8_4seq1.xml","form_type":"4"}},{"id":1415430,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36311,"kind":"person","name":"Thunen Shelley B","position":1,"cik":"0001297491","reported_name":"Thunen Shelley B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-09-05T01:51:54.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":36021,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units granted on August 31, 2024 (the \"Grant Date\"), which vests in full on the second anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":36021,"source":{"system":"sec-edgar","filing":"0001104659-24-097060","document":"tm2423415-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1297491/000110465924097060/tm2423415-8_4seq1.xml","form_type":"4"}},{"id":1416263,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36462,"kind":"person","name":"PALMISANO ROBERT J","position":1,"cik":"0001138646","reported_name":"PALMISANO ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-09-05T01:49:34.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":96210,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents an award of stock options granted on August 31, 2024 (the \"Grant Date\"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents an award of stock options granted on August 31, 2024 (the \"Grant Date\"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":96210,"derivative":{"exercise_price":0.83,"expiration_date":"2034-08-30","underlying":"Class A Common Stock","underlying_shares":96210},"source":{"system":"sec-edgar","filing":"0001104659-24-097059","document":"tm2423415-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1138646/000110465924097059/tm2423415-6_4seq1.xml","form_type":"4"}},{"id":1416262,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36462,"kind":"person","name":"PALMISANO ROBERT J","position":1,"cik":"0001138646","reported_name":"PALMISANO ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-09-05T01:49:34.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":36021,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units granted on August 31, 2024 (the \"Grant Date\"), which vests in full on the second anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":36021,"source":{"system":"sec-edgar","filing":"0001104659-24-097059","document":"tm2423415-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138646/000110465924097059/tm2423415-6_4seq1.xml","form_type":"4"}},{"id":1416058,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":61532,"kind":"person","name":"Oh Chad","position":1,"cik":"0001882166","reported_name":"Oh Chad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option","published_at":"2024-09-04T21:58:08.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":512673,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents an award of stock options granted on August 31, 2024 (the \"Grant Date\"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents an award of stock options granted on August 31, 2024 (the \"Grant Date\"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":512673,"derivative":{"exercise_price":0.83,"expiration_date":"2034-08-30","underlying":"Class A Common Stock","underlying_shares":512673},"source":{"system":"sec-edgar","filing":"0001104659-24-097064","document":"tm2423415-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882166/000110465924097064/tm2423415-5_4seq1.xml","form_type":"4"}},{"id":1416057,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":61532,"kind":"person","name":"Oh Chad","position":1,"cik":"0001882166","reported_name":"Oh Chad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Class A Common Stock","published_at":"2024-09-04T21:58:08.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":192117,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units granted on August 31, 2024 (the \"Grant Date\"), which vests in full on the second anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an award of restricted stock units (\"RSUs\") in the amount of 100,428 previously granted on April 26, 2023, which were previously reported on July 24, 2023 as derivative securities in Table II due to a clerical error, and which are now being reported as common stock in Table I. The vesting terms for the RSUs have not changed from what was previously reported on July 24, 2023."}],"balance_after":292545,"source":{"system":"sec-edgar","filing":"0001104659-24-097064","document":"tm2423415-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882166/000110465924097064/tm2423415-5_4seq1.xml","form_type":"4"}},{"id":1416211,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62603,"kind":"person","name":"Sy Jennifer","position":1,"cik":"0002023998","reported_name":"Sy Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock Option","published_at":"2024-09-04T21:53:47.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":48063,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents an award of stock options granted on August 31, 2024 (the \"Grant Date\"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents an award of stock options granted on August 31, 2024 (the \"Grant Date\"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":48063,"derivative":{"exercise_price":0.83,"expiration_date":"2034-08-30","underlying":"Class A Common Stock","underlying_shares":48063},"source":{"system":"sec-edgar","filing":"0001104659-24-097062","document":"tm2423415-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2023998/000110465924097062/tm2423415-4_4seq1.xml","form_type":"4"}},{"id":1416210,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62603,"kind":"person","name":"Sy Jennifer","position":1,"cik":"0002023998","reported_name":"Sy Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Class A Common Stock","published_at":"2024-09-04T21:53:47.000Z","date":"2024-08-31","kind":"grant","planned":false,"acquired":true,"shares":18010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units granted on August 31, 2024 (the \"Grant Date\"), which vests in full on the second anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":18010,"source":{"system":"sec-edgar","filing":"0001104659-24-097062","document":"tm2423415-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2023998/000110465924097062/tm2423415-4_4seq1.xml","form_type":"4"}},{"id":1540898,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":68484,"kind":"organization","name":"Daewoong Co., Ltd","position":1,"cik":"0001985493","reported_name":"Daewoong Co., Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Senior Secured Convertible Note","published_at":"2024-04-17T01:09:20.000Z","date":"2024-04-12","kind":"other","planned":false,"acquired":true,"reported_value":10000000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to a subscription agreement entered on March 24, 2024 into by and between Daewoong Pharmaceutical Co., Ltd. (\"DWP\"), AEON Biopharma, Inc. (\"AEON\" or the \"Company\") and AEON Biopharma Sub, Inc., a subsidiary of the Company (\"AEON Sub\"), and pursuant to the Company's compliance with certain conditions set forth in the subscription agreement, DWP acquired a senior secured convertible note (the \"Subsequent Convertible Note\" or \"$10.0 million Note\") in the principal amount of $10.0 million on April 12, 2024, which is convertible into shares of the Company's Class A common stock, par value $0.0001 (\"Common Stock\"), subject to certain conditions and limitations set forth in the $10.0 million Note."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"(continued from footnote [1]). The $10.0 million Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date that is three years from the funding date (the \"Maturity Date\"), unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date. If, prior to the Maturity Date, the Company consummates a bona-fide third-party financing in the form of Common Stock or any securities convertible into, or exchangeable or exercisable for, Common Stock (subject to certain exceptions as described the $10.0 million Note), in one or more transactions or a series of related and substantially similar and simultaneous transactions at the same purchase price from third parties unaffiliated with DWP and its affiliates, for aggregate gross cash proceeds to the Company of at least $30.0 million (a \"Qualified Financing\"),"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"(continued from footnote [2]). then, upon written notice thereof to DWP by the Company, on the closing date of such Qualified Financing, the $10.0 million Note will automatically convert in whole (the \"Automatic Conversion\") (subject to any limitations under the rules and regulations of NYSE American), without any further action by DWP, into a number of shares equal to: (i) one and three tenths (1.3) multiplied by (ii) the quotient of (a) the principal amount of the $10.0 million Note and all accrued and unpaid interest to be converted divided by (b) the per share price of the Common Stock sold in the Qualified Financing, provided that such per share price of Common Stock is at least $1.00 per share. Due to the terms and conditions for issuance of the Subsequent Convertible Note, the number and the price of Common Shares which would be received by the Reporting Person upon conversion of the $10.0 million Note is indeterminate."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a subscription agreement entered on March 24, 2024 into by and between Daewoong Pharmaceutical Co., Ltd. (\"DWP\"), AEON Biopharma, Inc. (\"AEON\" or the \"Company\") and AEON Biopharma Sub, Inc., a subsidiary of the Company (\"AEON Sub\"), and pursuant to the Company's compliance with certain conditions set forth in the subscription agreement, DWP acquired a senior secured convertible note (the \"Subsequent Convertible Note\" or \"$10.0 million Note\") in the principal amount of $10.0 million on April 12, 2024, which is convertible into shares of the Company's Class A common stock, par value $0.0001 (\"Common Stock\"), subject to certain conditions and limitations set forth in the $10.0 million Note."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote [1]). The $10.0 million Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date that is three years from the funding date (the \"Maturity Date\"), unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date. If, prior to the Maturity Date, the Company consummates a bona-fide third-party financing in the form of Common Stock or any securities convertible into, or exchangeable or exercisable for, Common Stock (subject to certain exceptions as described the $10.0 million Note), in one or more transactions or a series of related and substantially similar and simultaneous transactions at the same purchase price from third parties unaffiliated with DWP and its affiliates, for aggregate gross cash proceeds to the Company of at least $30.0 million (a \"Qualified Financing\"),"},{"field":"kind","element":"transactionCoding","label":"F3","text":"(continued from footnote [2]). then, upon written notice thereof to DWP by the Company, on the closing date of such Qualified Financing, the $10.0 million Note will automatically convert in whole (the \"Automatic Conversion\") (subject to any limitations under the rules and regulations of NYSE American), without any further action by DWP, into a number of shares equal to: (i) one and three tenths (1.3) multiplied by (ii) the quotient of (a) the principal amount of the $10.0 million Note and all accrued and unpaid interest to be converted divided by (b) the per share price of the Common Stock sold in the Qualified Financing, provided that such per share price of Common Stock is at least $1.00 per share. Due to the terms and conditions for issuance of the Subsequent Convertible Note, the number and the price of Common Shares which would be received by the Reporting Person upon conversion of the $10.0 million Note is indeterminate."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Daewoong Co., Ltd., a company organized under the laws of the Republic of Korea, owns 52% of the outstanding shares of Daewoong Pharmaceutical Co., Ltd., a company organized under the laws of the Republic of Korea; Daewoong Co., Ltd. has voting power and dispositive power over Daewoong Pharmaceutical Co., Ltd. and therefore may be deemed to indirectly own such shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a subscription agreement entered on March 24, 2024 into by and between Daewoong Pharmaceutical Co., Ltd. (\"DWP\"), AEON Biopharma, Inc. (\"AEON\" or the \"Company\") and AEON Biopharma Sub, Inc., a subsidiary of the Company (\"AEON Sub\"), and pursuant to the Company's compliance with certain conditions set forth in the subscription agreement, DWP acquired a senior secured convertible note (the \"Subsequent Convertible Note\" or \"$10.0 million Note\") in the principal amount of $10.0 million on April 12, 2024, which is convertible into shares of the Company's Class A common stock, par value $0.0001 (\"Common Stock\"), subject to certain conditions and limitations set forth in the $10.0 million Note."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote [1]). The $10.0 million Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date that is three years from the funding date (the \"Maturity Date\"), unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date. If, prior to the Maturity Date, the Company consummates a bona-fide third-party financing in the form of Common Stock or any securities convertible into, or exchangeable or exercisable for, Common Stock (subject to certain exceptions as described the $10.0 million Note), in one or more transactions or a series of related and substantially similar and simultaneous transactions at the same purchase price from third parties unaffiliated with DWP and its affiliates, for aggregate gross cash proceeds to the Company of at least $30.0 million (a \"Qualified Financing\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from footnote [2]). then, upon written notice thereof to DWP by the Company, on the closing date of such Qualified Financing, the $10.0 million Note will automatically convert in whole (the \"Automatic Conversion\") (subject to any limitations under the rules and regulations of NYSE American), without any further action by DWP, into a number of shares equal to: (i) one and three tenths (1.3) multiplied by (ii) the quotient of (a) the principal amount of the $10.0 million Note and all accrued and unpaid interest to be converted divided by (b) the per share price of the Common Stock sold in the Qualified Financing, provided that such per share price of Common Stock is at least $1.00 per share. Due to the terms and conditions for issuance of the Subsequent Convertible Note, the number and the price of Common Shares which would be received by the Reporting Person upon conversion of the $10.0 million Note is indeterminate."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to a subscription agreement entered on March 24, 2024 into by and between Daewoong Pharmaceutical Co., Ltd. (\"DWP\"), AEON Biopharma, Inc. (\"AEON\" or the \"Company\") and AEON Biopharma Sub, Inc., a subsidiary of the Company (\"AEON Sub\"), and pursuant to the Company's compliance with certain conditions set forth in the subscription agreement, DWP acquired a senior secured convertible note (the \"Subsequent Convertible Note\" or \"$10.0 million Note\") in the principal amount of $10.0 million on April 12, 2024, which is convertible into shares of the Company's Class A common stock, par value $0.0001 (\"Common Stock\"), subject to certain conditions and limitations set forth in the $10.0 million Note."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from footnote [1]). The $10.0 million Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date that is three years from the funding date (the \"Maturity Date\"), unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date. If, prior to the Maturity Date, the Company consummates a bona-fide third-party financing in the form of Common Stock or any securities convertible into, or exchangeable or exercisable for, Common Stock (subject to certain exceptions as described the $10.0 million Note), in one or more transactions or a series of related and substantially similar and simultaneous transactions at the same purchase price from third parties unaffiliated with DWP and its affiliates, for aggregate gross cash proceeds to the Company of at least $30.0 million (a \"Qualified Financing\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from footnote [2]). then, upon written notice thereof to DWP by the Company, on the closing date of such Qualified Financing, the $10.0 million Note will automatically convert in whole (the \"Automatic Conversion\") (subject to any limitations under the rules and regulations of NYSE American), without any further action by DWP, into a number of shares equal to: (i) one and three tenths (1.3) multiplied by (ii) the quotient of (a) the principal amount of the $10.0 million Note and all accrued and unpaid interest to be converted divided by (b) the per share price of the Common Stock sold in the Qualified Financing, provided that such per share price of Common Stock is at least $1.00 per share. Due to the terms and conditions for issuance of the Subsequent Convertible Note, the number and the price of Common Shares which would be received by the Reporting Person upon conversion of the $10.0 million Note is indeterminate."},{"field":"underlyingValue","element":"underlyingSecurityValue","label":"F1","text":"Pursuant to a subscription agreement entered on March 24, 2024 into by and between Daewoong Pharmaceutical Co., Ltd. (\"DWP\"), AEON Biopharma, Inc. (\"AEON\" or the \"Company\") and AEON Biopharma Sub, Inc., a subsidiary of the Company (\"AEON Sub\"), and pursuant to the Company's compliance with certain conditions set forth in the subscription agreement, DWP acquired a senior secured convertible note (the \"Subsequent Convertible Note\" or \"$10.0 million Note\") in the principal amount of $10.0 million on April 12, 2024, which is convertible into shares of the Company's Class A common stock, par value $0.0001 (\"Common Stock\"), subject to certain conditions and limitations set forth in the $10.0 million Note."},{"field":"underlyingValue","element":"underlyingSecurityValue","label":"F2","text":"(continued from footnote [1]). The $10.0 million Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date that is three years from the funding date (the \"Maturity Date\"), unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date. If, prior to the Maturity Date, the Company consummates a bona-fide third-party financing in the form of Common Stock or any securities convertible into, or exchangeable or exercisable for, Common Stock (subject to certain exceptions as described the $10.0 million Note), in one or more transactions or a series of related and substantially similar and simultaneous transactions at the same purchase price from third parties unaffiliated with DWP and its affiliates, for aggregate gross cash proceeds to the Company of at least $30.0 million (a \"Qualified Financing\"),"},{"field":"underlyingValue","element":"underlyingSecurityValue","label":"F3","text":"(continued from footnote [2]). then, upon written notice thereof to DWP by the Company, on the closing date of such Qualified Financing, the $10.0 million Note will automatically convert in whole (the \"Automatic Conversion\") (subject to any limitations under the rules and regulations of NYSE American), without any further action by DWP, into a number of shares equal to: (i) one and three tenths (1.3) multiplied by (ii) the quotient of (a) the principal amount of the $10.0 million Note and all accrued and unpaid interest to be converted divided by (b) the per share price of the Common Stock sold in the Qualified Financing, provided that such per share price of Common Stock is at least $1.00 per share. Due to the terms and conditions for issuance of the Subsequent Convertible Note, the number and the price of Common Shares which would be received by the Reporting Person upon conversion of the $10.0 million Note is indeterminate."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Daewoong Co., Ltd., a company organized under the laws of the Republic of Korea, owns 52% of the outstanding shares of Daewoong Pharmaceutical Co., Ltd., a company organized under the laws of the Republic of Korea; Daewoong Co., Ltd. has voting power and dispositive power over Daewoong Pharmaceutical Co., Ltd. and therefore may be deemed to indirectly own such shares."}],"derivative":{"expiration_date":"2027-04-12","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001213900-24-033564","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000121390024033564/ownership.xml","form_type":"4/A","original_submission_date":"2024-04-12"}},{"id":1542347,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":68484,"kind":"organization","name":"Daewoong Co., Ltd","position":1,"cik":"0001985493","reported_name":"Daewoong Co., Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Senior Secured Convertible Note","published_at":"2024-04-12T11:00:56.000Z","date":"2024-04-11","kind":"other","planned":false,"acquired":true,"reported_value":10000000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to a subscription agreement entered on March 24, 2024 into by and between Daewoong Pharmaceutical Co., Ltd. (\"DWP\"), AEON Biopharma, Inc. (\"AEON\" or the \"Company\") and AEON Biopharma Sub, Inc., a subsidiary of the Company (\"AEON Sub\"), and pursuant to the Company's compliance with certain conditions set forth in the subscription agreement, DWP acquired a senior secured convertible note (the \"Subsequent Convertible Note\" or \"$10.0 million Note\") in the principal amount of $10.0 million on April 11, 2024, which is convertible into shares of the Company's Class A common stock, par value $0.0001 (\"Common Stock\"), subject to certain conditions and limitations set forth in the $10.0 million Note."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"(continued from footnote [1]). The $10.0 million Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date that is three years from the funding date (the \"Maturity Date\"), unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date. If, prior to the Maturity Date, the Company consummates a bona-fide third-party financing in the form of Common Stock or any securities convertible into, or exchangeable or exercisable for, Common Stock (subject to certain exceptions as described the $10.0 million Note), in one or more transactions or a series of related and substantially similar and simultaneous transactions at the same purchase price from third parties unaffiliated with DWP and its affiliates, for aggregate gross cash proceeds to the Company of at least $30.0 million (a \"Qualified Financing\"),"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"(continued from footnote [2]). then, upon written notice thereof to DWP by the Company, on the closing date of such Qualified Financing, the $10.0 million Note will automatically convert in whole (the \"Automatic Conversion\") (subject to any limitations under the rules and regulations of NYSE American), without any further action by DWP, into a number of shares equal to: (i) one and three tenths (1.3) multiplied by (ii) the quotient of (a) the principal amount of the $10.0 million Note and all accrued and unpaid interest to be converted divided by (b) the per share price of the Common Stock sold in the Qualified Financing, provided that such per share price of Common Stock is at least $1.00 per share. Due to the terms and conditions for issuance of the Subsequent Convertible Note, the number and the price of Common Shares which would be received by the Reporting Person upon conversion of the $10.0 million Note is indeterminate."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a subscription agreement entered on March 24, 2024 into by and between Daewoong Pharmaceutical Co., Ltd. (\"DWP\"), AEON Biopharma, Inc. (\"AEON\" or the \"Company\") and AEON Biopharma Sub, Inc., a subsidiary of the Company (\"AEON Sub\"), and pursuant to the Company's compliance with certain conditions set forth in the subscription agreement, DWP acquired a senior secured convertible note (the \"Subsequent Convertible Note\" or \"$10.0 million Note\") in the principal amount of $10.0 million on April 11, 2024, which is convertible into shares of the Company's Class A common stock, par value $0.0001 (\"Common Stock\"), subject to certain conditions and limitations set forth in the $10.0 million Note."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote [1]). The $10.0 million Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date that is three years from the funding date (the \"Maturity Date\"), unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date. If, prior to the Maturity Date, the Company consummates a bona-fide third-party financing in the form of Common Stock or any securities convertible into, or exchangeable or exercisable for, Common Stock (subject to certain exceptions as described the $10.0 million Note), in one or more transactions or a series of related and substantially similar and simultaneous transactions at the same purchase price from third parties unaffiliated with DWP and its affiliates, for aggregate gross cash proceeds to the Company of at least $30.0 million (a \"Qualified Financing\"),"},{"field":"kind","element":"transactionCoding","label":"F3","text":"(continued from footnote [2]). then, upon written notice thereof to DWP by the Company, on the closing date of such Qualified Financing, the $10.0 million Note will automatically convert in whole (the \"Automatic Conversion\") (subject to any limitations under the rules and regulations of NYSE American), without any further action by DWP, into a number of shares equal to: (i) one and three tenths (1.3) multiplied by (ii) the quotient of (a) the principal amount of the $10.0 million Note and all accrued and unpaid interest to be converted divided by (b) the per share price of the Common Stock sold in the Qualified Financing, provided that such per share price of Common Stock is at least $1.00 per share. Due to the terms and conditions for issuance of the Subsequent Convertible Note, the number and the price of Common Shares which would be received by the Reporting Person upon conversion of the $10.0 million Note is indeterminate."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Daewoong Co., Ltd., a company organized under the laws of the Republic of Korea, owns 52% of the outstanding shares of Daewoong Pharmaceutical Co., Ltd., a company organized under the laws of the Republic of Korea; Daewoong Co., Ltd. has voting power and dispositive power over Daewoong Pharmaceutical Co., Ltd. and therefore may be deemed to indirectly own such shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a subscription agreement entered on March 24, 2024 into by and between Daewoong Pharmaceutical Co., Ltd. (\"DWP\"), AEON Biopharma, Inc. (\"AEON\" or the \"Company\") and AEON Biopharma Sub, Inc., a subsidiary of the Company (\"AEON Sub\"), and pursuant to the Company's compliance with certain conditions set forth in the subscription agreement, DWP acquired a senior secured convertible note (the \"Subsequent Convertible Note\" or \"$10.0 million Note\") in the principal amount of $10.0 million on April 11, 2024, which is convertible into shares of the Company's Class A common stock, par value $0.0001 (\"Common Stock\"), subject to certain conditions and limitations set forth in the $10.0 million Note."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote [1]). The $10.0 million Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date that is three years from the funding date (the \"Maturity Date\"), unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date. If, prior to the Maturity Date, the Company consummates a bona-fide third-party financing in the form of Common Stock or any securities convertible into, or exchangeable or exercisable for, Common Stock (subject to certain exceptions as described the $10.0 million Note), in one or more transactions or a series of related and substantially similar and simultaneous transactions at the same purchase price from third parties unaffiliated with DWP and its affiliates, for aggregate gross cash proceeds to the Company of at least $30.0 million (a \"Qualified Financing\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from footnote [2]). then, upon written notice thereof to DWP by the Company, on the closing date of such Qualified Financing, the $10.0 million Note will automatically convert in whole (the \"Automatic Conversion\") (subject to any limitations under the rules and regulations of NYSE American), without any further action by DWP, into a number of shares equal to: (i) one and three tenths (1.3) multiplied by (ii) the quotient of (a) the principal amount of the $10.0 million Note and all accrued and unpaid interest to be converted divided by (b) the per share price of the Common Stock sold in the Qualified Financing, provided that such per share price of Common Stock is at least $1.00 per share. Due to the terms and conditions for issuance of the Subsequent Convertible Note, the number and the price of Common Shares which would be received by the Reporting Person upon conversion of the $10.0 million Note is indeterminate."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to a subscription agreement entered on March 24, 2024 into by and between Daewoong Pharmaceutical Co., Ltd. (\"DWP\"), AEON Biopharma, Inc. (\"AEON\" or the \"Company\") and AEON Biopharma Sub, Inc., a subsidiary of the Company (\"AEON Sub\"), and pursuant to the Company's compliance with certain conditions set forth in the subscription agreement, DWP acquired a senior secured convertible note (the \"Subsequent Convertible Note\" or \"$10.0 million Note\") in the principal amount of $10.0 million on April 11, 2024, which is convertible into shares of the Company's Class A common stock, par value $0.0001 (\"Common Stock\"), subject to certain conditions and limitations set forth in the $10.0 million Note."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from footnote [1]). The $10.0 million Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date that is three years from the funding date (the \"Maturity Date\"), unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date. If, prior to the Maturity Date, the Company consummates a bona-fide third-party financing in the form of Common Stock or any securities convertible into, or exchangeable or exercisable for, Common Stock (subject to certain exceptions as described the $10.0 million Note), in one or more transactions or a series of related and substantially similar and simultaneous transactions at the same purchase price from third parties unaffiliated with DWP and its affiliates, for aggregate gross cash proceeds to the Company of at least $30.0 million (a \"Qualified Financing\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from footnote [2]). then, upon written notice thereof to DWP by the Company, on the closing date of such Qualified Financing, the $10.0 million Note will automatically convert in whole (the \"Automatic Conversion\") (subject to any limitations under the rules and regulations of NYSE American), without any further action by DWP, into a number of shares equal to: (i) one and three tenths (1.3) multiplied by (ii) the quotient of (a) the principal amount of the $10.0 million Note and all accrued and unpaid interest to be converted divided by (b) the per share price of the Common Stock sold in the Qualified Financing, provided that such per share price of Common Stock is at least $1.00 per share. Due to the terms and conditions for issuance of the Subsequent Convertible Note, the number and the price of Common Shares which would be received by the Reporting Person upon conversion of the $10.0 million Note is indeterminate."},{"field":"underlyingValue","element":"underlyingSecurityValue","label":"F1","text":"Pursuant to a subscription agreement entered on March 24, 2024 into by and between Daewoong Pharmaceutical Co., Ltd. (\"DWP\"), AEON Biopharma, Inc. (\"AEON\" or the \"Company\") and AEON Biopharma Sub, Inc., a subsidiary of the Company (\"AEON Sub\"), and pursuant to the Company's compliance with certain conditions set forth in the subscription agreement, DWP acquired a senior secured convertible note (the \"Subsequent Convertible Note\" or \"$10.0 million Note\") in the principal amount of $10.0 million on April 11, 2024, which is convertible into shares of the Company's Class A common stock, par value $0.0001 (\"Common Stock\"), subject to certain conditions and limitations set forth in the $10.0 million Note."},{"field":"underlyingValue","element":"underlyingSecurityValue","label":"F2","text":"(continued from footnote [1]). The $10.0 million Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date that is three years from the funding date (the \"Maturity Date\"), unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date. If, prior to the Maturity Date, the Company consummates a bona-fide third-party financing in the form of Common Stock or any securities convertible into, or exchangeable or exercisable for, Common Stock (subject to certain exceptions as described the $10.0 million Note), in one or more transactions or a series of related and substantially similar and simultaneous transactions at the same purchase price from third parties unaffiliated with DWP and its affiliates, for aggregate gross cash proceeds to the Company of at least $30.0 million (a \"Qualified Financing\"),"},{"field":"underlyingValue","element":"underlyingSecurityValue","label":"F3","text":"(continued from footnote [2]). then, upon written notice thereof to DWP by the Company, on the closing date of such Qualified Financing, the $10.0 million Note will automatically convert in whole (the \"Automatic Conversion\") (subject to any limitations under the rules and regulations of NYSE American), without any further action by DWP, into a number of shares equal to: (i) one and three tenths (1.3) multiplied by (ii) the quotient of (a) the principal amount of the $10.0 million Note and all accrued and unpaid interest to be converted divided by (b) the per share price of the Common Stock sold in the Qualified Financing, provided that such per share price of Common Stock is at least $1.00 per share. Due to the terms and conditions for issuance of the Subsequent Convertible Note, the number and the price of Common Shares which would be received by the Reporting Person upon conversion of the $10.0 million Note is indeterminate."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Daewoong Co., Ltd., a company organized under the laws of the Republic of Korea, owns 52% of the outstanding shares of Daewoong Pharmaceutical Co., Ltd., a company organized under the laws of the Republic of Korea; Daewoong Co., Ltd. has voting power and dispositive power over Daewoong Pharmaceutical Co., Ltd. and therefore may be deemed to indirectly own such shares."}],"derivative":{"expiration_date":"2027-04-11","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001213900-24-032312","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000121390024032312/ownership.xml","form_type":"4"}},{"id":1560188,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":68484,"kind":"organization","name":"Daewoong Co., Ltd","position":1,"cik":"0001985493","reported_name":"Daewoong Co., Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Senior Secured Convertible Note","published_at":"2024-03-26T10:39:01.000Z","date":"2024-03-24","kind":"other","planned":false,"acquired":true,"reported_value":5000000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to a subscription agreement entered into by and between Daewoong Pharmaceutical Co., Ltd. (\"DWP\"), AEON Biopharma, Inc. (\"AEON\" or the \"Company\") and AEON Biopharma Sub, Inc., a subsidiary of the Company (\"AEON Sub\"), on March 24, 2024, DWP acquired a senior secured convertible note (the \"Convertible Note\" or \"$5.0 million Note\") in the principal amount of $5.0 million, which is convertible into shares of the Company's Class A common stock, par value $0.0001 (\"Common Stock\"), subject to certain conditions and limitations set forth in the $5.0 million Note. The $5.0 million Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date that is three years from the funding date (the \"Maturity Date\"), unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"(continued from footnote [1]). If, prior to the Maturity Date, the Company consummates a bona-fide third-party financing in the form of Common Stock or any securities convertible into, or exchangeable or exercisable for, Common Stock (subject to certain exceptions as described the $5.0 million Note), in one or more transactions or a series of related and substantially similar and simultaneous transactions at the same purchase price from third parties unaffiliated with DWP and its affiliates, for aggregate gross cash proceeds to the Company of at least $30.0 million (a \"Qualified Financing\"),"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"(continued from footnote [2]). then, upon written notice thereof to DWP by the Company, on the closing date of such Qualified Financing, the $5.0 million Note will automatically convert in whole (the \"Automatic Conversion\") (subject to any limitations under the rules and regulations of NYSE American), without any further action by DWP, into a number of shares equal to: (i) one and three tenths (1.3) multiplied by (ii) the quotient of (a) the principal amount of the $5.0 million Note and all accrued and unpaid interest to be converted divided by (b) the per share price of the Common Stock sold in the Qualified Financing, provided that such per share price of Common Stock is at least $1.00 per share. Due to the terms and conditions for issuance of the Convertible Note, the number and the price of Common Shares which would be received by the Reporting Person upon conversion of the $5.0 million Note is indeterminate."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a subscription agreement entered into by and between Daewoong Pharmaceutical Co., Ltd. (\"DWP\"), AEON Biopharma, Inc. (\"AEON\" or the \"Company\") and AEON Biopharma Sub, Inc., a subsidiary of the Company (\"AEON Sub\"), on March 24, 2024, DWP acquired a senior secured convertible note (the \"Convertible Note\" or \"$5.0 million Note\") in the principal amount of $5.0 million, which is convertible into shares of the Company's Class A common stock, par value $0.0001 (\"Common Stock\"), subject to certain conditions and limitations set forth in the $5.0 million Note. The $5.0 million Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date that is three years from the funding date (the \"Maturity Date\"), unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote [1]). If, prior to the Maturity Date, the Company consummates a bona-fide third-party financing in the form of Common Stock or any securities convertible into, or exchangeable or exercisable for, Common Stock (subject to certain exceptions as described the $5.0 million Note), in one or more transactions or a series of related and substantially similar and simultaneous transactions at the same purchase price from third parties unaffiliated with DWP and its affiliates, for aggregate gross cash proceeds to the Company of at least $30.0 million (a \"Qualified Financing\"),"},{"field":"kind","element":"transactionCoding","label":"F3","text":"(continued from footnote [2]). then, upon written notice thereof to DWP by the Company, on the closing date of such Qualified Financing, the $5.0 million Note will automatically convert in whole (the \"Automatic Conversion\") (subject to any limitations under the rules and regulations of NYSE American), without any further action by DWP, into a number of shares equal to: (i) one and three tenths (1.3) multiplied by (ii) the quotient of (a) the principal amount of the $5.0 million Note and all accrued and unpaid interest to be converted divided by (b) the per share price of the Common Stock sold in the Qualified Financing, provided that such per share price of Common Stock is at least $1.00 per share. Due to the terms and conditions for issuance of the Convertible Note, the number and the price of Common Shares which would be received by the Reporting Person upon conversion of the $5.0 million Note is indeterminate."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Daewoong Co., Ltd., a company organized under the laws of the Republic of Korea, owns 52% of the outstanding shares of Daewoong Pharmaceutical Co., Ltd., a company organized under the laws of the Republic of Korea; Daewoong Co., Ltd. has voting power and dispositive power over Daewoong Pharmaceutical Co., Ltd. and therefore may be deemed to indirectly own such shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a subscription agreement entered into by and between Daewoong Pharmaceutical Co., Ltd. (\"DWP\"), AEON Biopharma, Inc. (\"AEON\" or the \"Company\") and AEON Biopharma Sub, Inc., a subsidiary of the Company (\"AEON Sub\"), on March 24, 2024, DWP acquired a senior secured convertible note (the \"Convertible Note\" or \"$5.0 million Note\") in the principal amount of $5.0 million, which is convertible into shares of the Company's Class A common stock, par value $0.0001 (\"Common Stock\"), subject to certain conditions and limitations set forth in the $5.0 million Note. The $5.0 million Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date that is three years from the funding date (the \"Maturity Date\"), unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote [1]). If, prior to the Maturity Date, the Company consummates a bona-fide third-party financing in the form of Common Stock or any securities convertible into, or exchangeable or exercisable for, Common Stock (subject to certain exceptions as described the $5.0 million Note), in one or more transactions or a series of related and substantially similar and simultaneous transactions at the same purchase price from third parties unaffiliated with DWP and its affiliates, for aggregate gross cash proceeds to the Company of at least $30.0 million (a \"Qualified Financing\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from footnote [2]). then, upon written notice thereof to DWP by the Company, on the closing date of such Qualified Financing, the $5.0 million Note will automatically convert in whole (the \"Automatic Conversion\") (subject to any limitations under the rules and regulations of NYSE American), without any further action by DWP, into a number of shares equal to: (i) one and three tenths (1.3) multiplied by (ii) the quotient of (a) the principal amount of the $5.0 million Note and all accrued and unpaid interest to be converted divided by (b) the per share price of the Common Stock sold in the Qualified Financing, provided that such per share price of Common Stock is at least $1.00 per share. Due to the terms and conditions for issuance of the Convertible Note, the number and the price of Common Shares which would be received by the Reporting Person upon conversion of the $5.0 million Note is indeterminate."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to a subscription agreement entered into by and between Daewoong Pharmaceutical Co., Ltd. (\"DWP\"), AEON Biopharma, Inc. (\"AEON\" or the \"Company\") and AEON Biopharma Sub, Inc., a subsidiary of the Company (\"AEON Sub\"), on March 24, 2024, DWP acquired a senior secured convertible note (the \"Convertible Note\" or \"$5.0 million Note\") in the principal amount of $5.0 million, which is convertible into shares of the Company's Class A common stock, par value $0.0001 (\"Common Stock\"), subject to certain conditions and limitations set forth in the $5.0 million Note. The $5.0 million Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date that is three years from the funding date (the \"Maturity Date\"), unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from footnote [1]). If, prior to the Maturity Date, the Company consummates a bona-fide third-party financing in the form of Common Stock or any securities convertible into, or exchangeable or exercisable for, Common Stock (subject to certain exceptions as described the $5.0 million Note), in one or more transactions or a series of related and substantially similar and simultaneous transactions at the same purchase price from third parties unaffiliated with DWP and its affiliates, for aggregate gross cash proceeds to the Company of at least $30.0 million (a \"Qualified Financing\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from footnote [2]). then, upon written notice thereof to DWP by the Company, on the closing date of such Qualified Financing, the $5.0 million Note will automatically convert in whole (the \"Automatic Conversion\") (subject to any limitations under the rules and regulations of NYSE American), without any further action by DWP, into a number of shares equal to: (i) one and three tenths (1.3) multiplied by (ii) the quotient of (a) the principal amount of the $5.0 million Note and all accrued and unpaid interest to be converted divided by (b) the per share price of the Common Stock sold in the Qualified Financing, provided that such per share price of Common Stock is at least $1.00 per share. Due to the terms and conditions for issuance of the Convertible Note, the number and the price of Common Shares which would be received by the Reporting Person upon conversion of the $5.0 million Note is indeterminate."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Pursuant to a subscription agreement entered into by and between Daewoong Pharmaceutical Co., Ltd. (\"DWP\"), AEON Biopharma, Inc. (\"AEON\" or the \"Company\") and AEON Biopharma Sub, Inc., a subsidiary of the Company (\"AEON Sub\"), on March 24, 2024, DWP acquired a senior secured convertible note (the \"Convertible Note\" or \"$5.0 million Note\") in the principal amount of $5.0 million, which is convertible into shares of the Company's Class A common stock, par value $0.0001 (\"Common Stock\"), subject to certain conditions and limitations set forth in the $5.0 million Note. The $5.0 million Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date that is three years from the funding date (the \"Maturity Date\"), unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"(continued from footnote [1]). If, prior to the Maturity Date, the Company consummates a bona-fide third-party financing in the form of Common Stock or any securities convertible into, or exchangeable or exercisable for, Common Stock (subject to certain exceptions as described the $5.0 million Note), in one or more transactions or a series of related and substantially similar and simultaneous transactions at the same purchase price from third parties unaffiliated with DWP and its affiliates, for aggregate gross cash proceeds to the Company of at least $30.0 million (a \"Qualified Financing\"),"},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"(continued from footnote [2]). then, upon written notice thereof to DWP by the Company, on the closing date of such Qualified Financing, the $5.0 million Note will automatically convert in whole (the \"Automatic Conversion\") (subject to any limitations under the rules and regulations of NYSE American), without any further action by DWP, into a number of shares equal to: (i) one and three tenths (1.3) multiplied by (ii) the quotient of (a) the principal amount of the $5.0 million Note and all accrued and unpaid interest to be converted divided by (b) the per share price of the Common Stock sold in the Qualified Financing, provided that such per share price of Common Stock is at least $1.00 per share. Due to the terms and conditions for issuance of the Convertible Note, the number and the price of Common Shares which would be received by the Reporting Person upon conversion of the $5.0 million Note is indeterminate."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Daewoong Co., Ltd., a company organized under the laws of the Republic of Korea, owns 52% of the outstanding shares of Daewoong Pharmaceutical Co., Ltd., a company organized under the laws of the Republic of Korea; Daewoong Co., Ltd. has voting power and dispositive power over Daewoong Pharmaceutical Co., Ltd. and therefore may be deemed to indirectly own such shares."}],"derivative":{"expiration_date":"2027-03-24","underlying":"Common Stock","underlying_shares":5000000},"source":{"system":"sec-edgar","filing":"0001213900-24-025744","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000121390024025744/ownership.xml","form_type":"4"}},{"id":1564690,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36311,"kind":"person","name":"Thunen Shelley B","position":1,"cik":"0001297491","reported_name":"Thunen Shelley B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-03-21T23:52:32.000Z","date":"2024-03-19","kind":"grant","planned":false,"acquired":true,"shares":16260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of stock options granted on March 19, 2024 (the \"Grant Date\"), which vests in substantially equal monthly installments over the one year following the Grant Date, subject to the reporting person's continued service through the applicable vesting date.  Each option will vest in full upon a Change in Control (as defined in the AEON Biopharma Inc. 2023 Incentive Award Plan) of the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of stock options granted on March 19, 2024 (the \"Grant Date\"), which vests in substantially equal monthly installments over the one year following the Grant Date, subject to the reporting person's continued service through the applicable vesting date.  Each option will vest in full upon a Change in Control (as defined in the AEON Biopharma Inc. 2023 Incentive Award Plan) of the Company."}],"balance_after":16260,"derivative":{"exercise_price":14.4,"expiration_date":"2034-03-18","underlying":"Common Stock","underlying_shares":16260},"source":{"system":"sec-edgar","filing":"0001104659-24-037441","document":"tm249503-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1297491/000110465924037441/tm249503-7_4seq1.xml","form_type":"4"}},{"id":1565034,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36462,"kind":"person","name":"PALMISANO ROBERT J","position":1,"cik":"0001138646","reported_name":"PALMISANO ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2024-03-21T23:51:04.000Z","date":"2024-03-19","kind":"grant","planned":false,"acquired":true,"shares":16260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of stock options granted on March 19, 2024 (the \"Grant Date\"), which vests in substantially equal monthly installments over the one year following the Grant Date, subject to the reporting person's continued service through the applicable vesting date. Each option will vest in full upon a Change in Control (as defined in the AEON Biopharma Inc. 2023 Incentive Award Plan) of the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of stock options granted on March 19, 2024 (the \"Grant Date\"), which vests in substantially equal monthly installments over the one year following the Grant Date, subject to the reporting person's continued service through the applicable vesting date. Each option will vest in full upon a Change in Control (as defined in the AEON Biopharma Inc. 2023 Incentive Award Plan) of the Company."}],"balance_after":16260,"derivative":{"exercise_price":14.4,"expiration_date":"2034-03-18","underlying":"Common Stock","underlying_shares":16260},"source":{"system":"sec-edgar","filing":"0001104659-24-037439","document":"tm249503-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138646/000110465924037439/tm249503-6_4seq1.xml","form_type":"4"}},{"id":1565298,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36519,"kind":"person","name":"Forth Marc","position":1,"cik":"0001816988","reported_name":"Forth Marc","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECTUIVE OFFICER"}}],"security":"Stock Option","published_at":"2024-03-21T23:49:40.000Z","date":"2024-03-19","kind":"grant","planned":false,"acquired":true,"shares":212466,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of stock options granted on March 19, 2024 (the \"Grant Date\"), which vests in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of stock options granted on March 19, 2024 (the \"Grant Date\"), which vests in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":212466,"derivative":{"exercise_price":14.4,"expiration_date":"2034-03-18","underlying":"Common Stock","underlying_shares":212466},"source":{"system":"sec-edgar","filing":"0001104659-24-037438","document":"tm249503-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816988/000110465924037438/tm249503-5_4seq1.xml","form_type":"4"}},{"id":1564623,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36267,"kind":"person","name":"FISCHER JOST","position":1,"cik":"0001366841","reported_name":"FISCHER JOST","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-03-21T23:46:31.000Z","date":"2024-03-19","kind":"grant","planned":false,"acquired":true,"shares":16260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of stock options granted on March 19, 2024 (the \"Grant Date\"), which vests in substantially equal monthly installments over the one year following the Grant Date, subject to the reporting person's continued service through the applicable vesting date. Each option will vest in full upon a Change in Control (as defined in the AEON Biopharma Inc. 2023 Incentive Award Plan) of the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of stock options granted on March 19, 2024 (the \"Grant Date\"), which vests in substantially equal monthly installments over the one year following the Grant Date, subject to the reporting person's continued service through the applicable vesting date. Each option will vest in full upon a Change in Control (as defined in the AEON Biopharma Inc. 2023 Incentive Award Plan) of the Company."}],"balance_after":16260,"derivative":{"exercise_price":14.4,"expiration_date":"2034-03-18","underlying":"Common Stock","underlying_shares":16260},"source":{"system":"sec-edgar","filing":"0001104659-24-037435","document":"tm249503-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366841/000110465924037435/tm249503-3_4seq1.xml","form_type":"4"}},{"id":1564612,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36264,"kind":"person","name":"Carter Eric G","position":1,"cik":"0001387660","reported_name":"Carter Eric G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-03-21T23:45:20.000Z","date":"2024-03-19","kind":"grant","planned":false,"acquired":true,"shares":8130,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of stock options granted on March 19, 2024 (the \"Grant Date\"), which vests in substantially equal monthly installments over the one year following the Grant Date, subject to the reporting person's continued service through the applicable vesting date.  Option will vest in full upon a Change in Control (as defined in the AEON Biopharma Inc. 2023 Incentive Award Plan) of the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents an award of stock options granted on March 19, 2024 (the \"Grant Date\"), which vests in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":8130,"derivative":{"exercise_price":14.4,"expiration_date":"2034-03-18","underlying":"Common Stock","underlying_shares":8130},"source":{"system":"sec-edgar","filing":"0001104659-24-037434","document":"tm249503-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1387660/000110465924037434/tm249503-2_4seq1.xml","form_type":"4"}},{"id":1564611,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36264,"kind":"person","name":"Carter Eric G","position":1,"cik":"0001387660","reported_name":"Carter Eric G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-03-21T23:45:20.000Z","date":"2024-03-19","kind":"grant","planned":false,"acquired":true,"shares":16260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of stock options granted on March 19, 2024 (the \"Grant Date\"), which vests in substantially equal monthly installments over the one year following the Grant Date, subject to the reporting person's continued service through the applicable vesting date.  Option will vest in full upon a Change in Control (as defined in the AEON Biopharma Inc. 2023 Incentive Award Plan) of the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of stock options granted on March 19, 2024 (the \"Grant Date\"), which vests in substantially equal monthly installments over the one year following the Grant Date, subject to the reporting person's continued service through the applicable vesting date.  Option will vest in full upon a Change in Control (as defined in the AEON Biopharma Inc. 2023 Incentive Award Plan) of the Company."}],"balance_after":16260,"derivative":{"exercise_price":14.4,"expiration_date":"2034-03-18","underlying":"Common Stock","underlying_shares":16260},"source":{"system":"sec-edgar","filing":"0001104659-24-037434","document":"tm249503-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1387660/000110465924037434/tm249503-2_4seq1.xml","form_type":"4"}},{"id":1564475,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62488,"kind":"person","name":"Wilson Alexander Blair","position":1,"cik":"0001979602","reported_name":"Wilson Alexander Blair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EXEC VP, CLO & CORP SECRETARY"}}],"security":"Stock Option","published_at":"2024-03-21T23:43:35.000Z","date":"2024-03-19","kind":"grant","planned":false,"acquired":true,"shares":81300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of stock options granted on March 19, 2024 (the \"Grant Date\"), which vests in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of stock options granted on March 19, 2024 (the \"Grant Date\"), which vests in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":81300,"derivative":{"exercise_price":14.4,"expiration_date":"2034-03-18","underlying":"Common Stock","underlying_shares":81300},"source":{"system":"sec-edgar","filing":"0001104659-24-037433","document":"tm249503-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465924037433/tm249503-1_4seq1.xml","form_type":"4"}},{"id":1564948,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":61532,"kind":"person","name":"Oh Chad","position":1,"cik":"0001882166","reported_name":"Oh Chad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option","published_at":"2024-03-21T19:48:02.000Z","date":"2024-03-19","kind":"grant","planned":false,"acquired":true,"shares":86720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of stock options granted on March 19, 2024 (the \"Grant Date\"), which vests in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of stock options granted on March 19, 2024 (the \"Grant Date\"), which vests in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":86720,"derivative":{"exercise_price":14.4,"expiration_date":"2034-03-18","underlying":"Common Stock","underlying_shares":86720},"source":{"system":"sec-edgar","filing":"0001104659-24-037436","document":"tm249503-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882166/000110465924037436/tm249503-4_4seq1.xml","form_type":"4"}},{"id":1805433,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36311,"kind":"person","name":"Thunen Shelley B","position":1,"cik":"0001297491","reported_name":"Thunen Shelley B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-08-16T20:07:20.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":58851,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of stock options on August 14, 2023, which vests in three yearly installments from August 14, 2023, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of stock options on August 14, 2023, which vests in three yearly installments from August 14, 2023, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":58851,"derivative":{"exercise_price":5.47,"expiration_date":"2033-08-13","underlying":"Common Stock","underlying_shares":58851},"source":{"system":"sec-edgar","filing":"0001104659-23-092551","document":"tm2323956-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1297491/000110465923092551/tm2323956-4_4seq1.xml","form_type":"4"}},{"id":1806150,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36462,"kind":"person","name":"PALMISANO ROBERT J","position":1,"cik":"0001138646","reported_name":"PALMISANO ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2023-08-16T20:06:36.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":58851,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of stock options on August 14, 2023, which vests in three yearly installments from August 14, 2023, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of stock options on August 14, 2023, which vests in three yearly installments from August 14, 2023, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":58851,"derivative":{"exercise_price":5.47,"expiration_date":"2033-08-13","underlying":"Common Stock","underlying_shares":58851},"source":{"system":"sec-edgar","filing":"0001104659-23-092548","document":"tm2323956-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138646/000110465923092548/tm2323956-3_4seq1.xml","form_type":"4"}},{"id":1805301,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36267,"kind":"person","name":"FISCHER JOST","position":1,"cik":"0001366841","reported_name":"FISCHER JOST","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-08-16T20:06:04.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":58851,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of stock options on August 14, 2023, which vests in 3 yearly installments from August 14, 2023, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of stock options on August 14, 2023, which vests in 3 yearly installments from August 14, 2023, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":58851,"derivative":{"exercise_price":5.47,"expiration_date":"2033-08-13","underlying":"Common Stock","underlying_shares":58851},"source":{"system":"sec-edgar","filing":"0001104659-23-092546","document":"tm2323956-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366841/000110465923092546/tm2323956-2_4seq1.xml","form_type":"4"}},{"id":1805268,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36264,"kind":"person","name":"Carter Eric G","position":1,"cik":"0001387660","reported_name":"Carter Eric G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-08-16T20:05:23.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":58851,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of stock options on August 14, 2023, which vests in three yearly installments from August 14, 2023, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of stock options on August 14, 2023, which vests in three yearly installments from August 14, 2023, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":58851,"derivative":{"exercise_price":5.47,"expiration_date":"2033-08-13","underlying":"Common Stock","underlying_shares":58851},"source":{"system":"sec-edgar","filing":"0001104659-23-092542","document":"tm2323956-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1387660/000110465923092542/tm2323956-1_4seq1.xml","form_type":"4"}},{"id":1808253,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":110566,"kind":"organization","name":"Strathspey Crown Holdings Group, LLC","position":1,"cik":"0001557024","reported_name":"Strathspey Crown Holdings Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2023-08-14T16:10:49.000Z","date":"2023-08-11","kind":"sale","planned":false,"acquired":false,"shares":7380394,"price":10,"value":73803940.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the disposition of shares of the Issuer's Class A Common Stock (the \"Distributed Shares\") by the Reporting Person in connection with the repurchase of certain of the Reporting Person's membership interests held by its members in exchange for, among other consideration, the Distributed Shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In addition to the disposition of the Distributed Shares, the amount reflected includes a reduction in the Reporting Person's beneficial ownership by an additional 8,203 shares of the Issuer's Class A Common Stock to correct an inadvertent overstatement of such ownership by such amount in the Reporting Person's Form 3 filed with the Securities and Exchange Commission on July 31, 2023."}],"balance_after":2031773,"source":{"system":"sec-edgar","filing":"0001477932-23-006094","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557024/000147793223006094/form4.xml","form_type":"4"}},{"id":1822966,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":111134,"kind":"organization","name":"Priveterra Sponsor, LLC","position":1,"cik":"0001843128","reported_name":"Priveterra Sponsor, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111135,"kind":"person","name":"Grodnensky Oleg","position":2,"cik":"0001843167","reported_name":"Grodnensky Oleg","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36462,"kind":"person","name":"PALMISANO ROBERT J","position":3,"cik":"0001138646","reported_name":"PALMISANO ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":65622,"kind":"person","name":"Malik Vikram","position":4,"cik":"0001730123","reported_name":"Malik Vikram","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-07-26T21:06:50.000Z","date":"2023-07-21","kind":"exercise","planned":false,"acquired":true,"shares":77453,"ownership":{"direct":false,"nature":"Held by Vikram Malik"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F14","text":"At the Effective Time, each outstanding award of restricted stock unit (\"RSU\") representing the contingent right to receive shares of AEON common stock (each an \"AEON RSU\") was automatically cancelled and converted into an RSU representing the contingent right to receive a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON RSU multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F15","text":"Represents an award of RSUs on April 26, 2023, which vests 6.25% vests upon the achievement of a first earnout goal, 25% upon the achievement of a second earnout goal, 25% upon the achievement of a third earnout, and 43.75% upon achievement of a fourth earnout goal. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."},{"field":"shares","element":"transactionShares","label":"F14","text":"At the Effective Time, each outstanding award of restricted stock unit (\"RSU\") representing the contingent right to receive shares of AEON common stock (each an \"AEON RSU\") was automatically cancelled and converted into an RSU representing the contingent right to receive a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON RSU multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F15","text":"Represents an award of RSUs on April 26, 2023, which vests 6.25% vests upon the achievement of a first earnout goal, 25% upon the achievement of a second earnout goal, 25% upon the achievement of a third earnout, and 43.75% upon achievement of a fourth earnout goal. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"Represents an award of RSUs on April 26, 2023, which vests 6.25% vests upon the achievement of a first earnout goal, 25% upon the achievement of a second earnout goal, 25% upon the achievement of a third earnout, and 43.75% upon achievement of a fourth earnout goal. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"Represents an award of RSUs on April 26, 2023, which vests 6.25% vests upon the achievement of a first earnout goal, 25% upon the achievement of a second earnout goal, 25% upon the achievement of a third earnout, and 43.75% upon achievement of a fourth earnout goal. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F15","text":"Represents an award of RSUs on April 26, 2023, which vests 6.25% vests upon the achievement of a first earnout goal, 25% upon the achievement of a second earnout goal, 25% upon the achievement of a third earnout, and 43.75% upon achievement of a fourth earnout goal. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."}],"balance_after":77453,"derivative":{"underlying":"Stock Options","underlying_shares":77453},"source":{"system":"sec-edgar","filing":"0000950103-23-010810","document":"dp197251_4-psllc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1138646/000095010323010810/dp197251_4-psllc.xml","form_type":"4"}},{"id":1822965,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":111134,"kind":"organization","name":"Priveterra Sponsor, LLC","position":1,"cik":"0001843128","reported_name":"Priveterra Sponsor, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111135,"kind":"person","name":"Grodnensky Oleg","position":2,"cik":"0001843167","reported_name":"Grodnensky Oleg","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36462,"kind":"person","name":"PALMISANO ROBERT J","position":3,"cik":"0001138646","reported_name":"PALMISANO ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":65622,"kind":"person","name":"Malik Vikram","position":4,"cik":"0001730123","reported_name":"Malik Vikram","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2023-07-26T21:06:50.000Z","date":"2023-07-21","kind":"exercise","planned":false,"acquired":true,"shares":7765,"ownership":{"direct":false,"nature":"Held by Vikram Malik"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer at a per-share exercise price of $10 per share."},{"field":"shares","element":"transactionShares","label":"F13","text":"Represents an award of stock options granted on March 9, 2022, which vests in three yearly installments from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Represents an award of stock options granted on March 9, 2022, which vests in three yearly installments from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."}],"balance_after":7765,"derivative":{"underlying":"Stock Options","underlying_shares":7765},"source":{"system":"sec-edgar","filing":"0000950103-23-010810","document":"dp197251_4-psllc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1138646/000095010323010810/dp197251_4-psllc.xml","form_type":"4"}},{"id":1822964,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":111134,"kind":"organization","name":"Priveterra Sponsor, LLC","position":1,"cik":"0001843128","reported_name":"Priveterra Sponsor, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111135,"kind":"person","name":"Grodnensky Oleg","position":2,"cik":"0001843167","reported_name":"Grodnensky Oleg","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36462,"kind":"person","name":"PALMISANO ROBERT J","position":3,"cik":"0001138646","reported_name":"PALMISANO ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":65622,"kind":"person","name":"Malik Vikram","position":4,"cik":"0001730123","reported_name":"Malik Vikram","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2023-07-26T21:06:50.000Z","date":"2023-07-21","kind":"exercise","planned":false,"acquired":true,"shares":21198,"ownership":{"direct":false,"nature":"Held by Vikram Malik"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer at a per-share exercise price of $10 per share."},{"field":"shares","element":"transactionShares","label":"F12","text":"Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."}],"balance_after":21198,"derivative":{"underlying":"Stock Options","underlying_shares":21198},"source":{"system":"sec-edgar","filing":"0000950103-23-010810","document":"dp197251_4-psllc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1138646/000095010323010810/dp197251_4-psllc.xml","form_type":"4"}},{"id":1822963,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":111134,"kind":"organization","name":"Priveterra Sponsor, LLC","position":1,"cik":"0001843128","reported_name":"Priveterra Sponsor, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111135,"kind":"person","name":"Grodnensky Oleg","position":2,"cik":"0001843167","reported_name":"Grodnensky Oleg","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36462,"kind":"person","name":"PALMISANO ROBERT J","position":3,"cik":"0001138646","reported_name":"PALMISANO ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":65622,"kind":"person","name":"Malik Vikram","position":4,"cik":"0001730123","reported_name":"Malik Vikram","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2023-07-26T21:06:50.000Z","date":"2023-07-21","kind":"exercise","planned":false,"acquired":true,"shares":19800,"ownership":{"direct":false,"nature":"Held by Vikram Malik"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer at a per-share exercise price of $10 per share."},{"field":"shares","element":"transactionShares","label":"F11","text":"Represents an award of stock options granted on March 5, 2021, which vested ratably over one year from March 5, 2021. Such options expire on March 5, 2031. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents an award of stock options granted on March 5, 2021, which vested ratably over one year from March 5, 2021. Such options expire on March 5, 2031. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."}],"balance_after":19800,"derivative":{"underlying":"Stock Options","underlying_shares":19800},"source":{"system":"sec-edgar","filing":"0000950103-23-010810","document":"dp197251_4-psllc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1138646/000095010323010810/dp197251_4-psllc.xml","form_type":"4"}},{"id":1822962,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":111134,"kind":"organization","name":"Priveterra Sponsor, LLC","position":1,"cik":"0001843128","reported_name":"Priveterra Sponsor, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111135,"kind":"person","name":"Grodnensky Oleg","position":2,"cik":"0001843167","reported_name":"Grodnensky Oleg","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36462,"kind":"person","name":"PALMISANO ROBERT J","position":3,"cik":"0001138646","reported_name":"PALMISANO ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":65622,"kind":"person","name":"Malik Vikram","position":4,"cik":"0001730123","reported_name":"Malik Vikram","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2023-07-26T21:06:50.000Z","date":"2023-07-21","kind":"exercise","planned":false,"acquired":true,"shares":21974,"ownership":{"direct":false,"nature":"Held by Vikram Malik"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer at a per-share exercise price of $10 per share."},{"field":"shares","element":"transactionShares","label":"F10","text":"Represents an award of stock options granted on August 5, 2020, which vested ratably over one year from March 4, 2020. Such options expire on August 1, 2030. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents an award of stock options granted on August 5, 2020, which vested ratably over one year from March 4, 2020. Such options expire on August 1, 2030. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."}],"balance_after":21974,"derivative":{"underlying":"Stock Options","underlying_shares":21974},"source":{"system":"sec-edgar","filing":"0000950103-23-010810","document":"dp197251_4-psllc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1138646/000095010323010810/dp197251_4-psllc.xml","form_type":"4"}},{"id":1822961,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":111134,"kind":"organization","name":"Priveterra Sponsor, LLC","position":1,"cik":"0001843128","reported_name":"Priveterra Sponsor, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111135,"kind":"person","name":"Grodnensky Oleg","position":2,"cik":"0001843167","reported_name":"Grodnensky Oleg","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36462,"kind":"person","name":"PALMISANO ROBERT J","position":3,"cik":"0001138646","reported_name":"PALMISANO ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":65622,"kind":"person","name":"Malik Vikram","position":4,"cik":"0001730123","reported_name":"Malik Vikram","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2023-07-26T21:06:50.000Z","date":"2023-07-21","kind":"exercise","planned":false,"acquired":true,"shares":38824,"ownership":{"direct":false,"nature":"Held by Vikram Malik"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer at a per-share exercise price of $10 per share."},{"field":"shares","element":"transactionShares","label":"F9","text":"Represents an award of stock options granted on November 20, 2019, which vested in three yearly installments from November 1, 2019. Such options expire on November 20, 2029. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents an award of stock options granted on November 20, 2019, which vested in three yearly installments from November 1, 2019. Such options expire on November 20, 2029. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."}],"balance_after":38824,"derivative":{"underlying":"Stock Options","underlying_shares":38824},"source":{"system":"sec-edgar","filing":"0000950103-23-010810","document":"dp197251_4-psllc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1138646/000095010323010810/dp197251_4-psllc.xml","form_type":"4"}},{"id":1822960,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":111134,"kind":"organization","name":"Priveterra Sponsor, LLC","position":1,"cik":"0001843128","reported_name":"Priveterra Sponsor, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111135,"kind":"person","name":"Grodnensky Oleg","position":2,"cik":"0001843167","reported_name":"Grodnensky Oleg","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36462,"kind":"person","name":"PALMISANO ROBERT J","position":3,"cik":"0001138646","reported_name":"PALMISANO ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":65622,"kind":"person","name":"Malik Vikram","position":4,"cik":"0001730123","reported_name":"Malik Vikram","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2023-07-26T21:06:50.000Z","date":"2023-07-21","kind":"exercise","planned":false,"acquired":true,"shares":38824,"ownership":{"direct":false,"nature":"Held by Oleg Grodnensky"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer at a per-share exercise price of $10 per share."},{"field":"shares","element":"transactionShares","label":"F9","text":"Represents an award of stock options granted on November 20, 2019, which vested in three yearly installments from November 1, 2019. Such options expire on November 20, 2029. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents an award of stock options granted on November 20, 2019, which vested in three yearly installments from November 1, 2019. Such options expire on November 20, 2029. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."}],"balance_after":38824,"derivative":{"underlying":"Stock Options","underlying_shares":38824},"source":{"system":"sec-edgar","filing":"0000950103-23-010810","document":"dp197251_4-psllc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1138646/000095010323010810/dp197251_4-psllc.xml","form_type":"4"}},{"id":1822959,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":111134,"kind":"organization","name":"Priveterra Sponsor, LLC","position":1,"cik":"0001843128","reported_name":"Priveterra Sponsor, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111135,"kind":"person","name":"Grodnensky Oleg","position":2,"cik":"0001843167","reported_name":"Grodnensky Oleg","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36462,"kind":"person","name":"PALMISANO ROBERT J","position":3,"cik":"0001138646","reported_name":"PALMISANO ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":65622,"kind":"person","name":"Malik Vikram","position":4,"cik":"0001730123","reported_name":"Malik Vikram","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Private Placement Warrants","published_at":"2023-07-26T21:06:50.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":false,"shares":5280000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"As described in the Issuer's Registration Statement on Form S-1 (File No. 333-252310) filed with the Securities and Exchange Commission on January 21, 2021, the Private Placement Warrants are identical to the warrants sold in connection with the Issuer's IPO, except that (i) the Private Placement Warrants (including shares of Class A common stock issuable upon exercise of the private placement warrants) will not be transferable, assignable or salable until 30 days after the completion of the Initial Business Combination (except, among other limited exceptions, to Priveterra's officers and directors, the Sponsor, or any of its or their respective permitted transferees);"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"(ii) the Private Placement Warrants will not be redeemable by the Issuer so long as they are held by the Sponsor, Priveterra's officers or directors, or its or their respective permitted transferees (except as set forth in the warrant agreement), (iii) the Private Placement Warrants may be exercised by the Sponsor, Priveterra's officers and directors, or its or their respective permitted transferees on a cashless basis, (iv) if the private placement warrants are held by holders other than the Sponsor, Priveterra's officers and directors, or its or their permitted transferees, the Private Placement Warrants will be redeemable by the Issuer and exercisable by the holders on the same basis as the public warrants; and (v) the Private Placement Warrants (including shares of Class A common stock issuable upon exercise of the private placement warrants) are entitled to registration rights."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As described in the Issuer's Registration Statement on Form S-1 (File No. 333-252310) filed with the Securities and Exchange Commission on January 21, 2021, the Private Placement Warrants are identical to the warrants sold in connection with the Issuer's IPO, except that (i) the Private Placement Warrants (including shares of Class A common stock issuable upon exercise of the private placement warrants) will not be transferable, assignable or salable until 30 days after the completion of the Initial Business Combination (except, among other limited exceptions, to Priveterra's officers and directors, the Sponsor, or any of its or their respective permitted transferees);"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(ii) the Private Placement Warrants will not be redeemable by the Issuer so long as they are held by the Sponsor, Priveterra's officers or directors, or its or their respective permitted transferees (except as set forth in the warrant agreement), (iii) the Private Placement Warrants may be exercised by the Sponsor, Priveterra's officers and directors, or its or their respective permitted transferees on a cashless basis, (iv) if the private placement warrants are held by holders other than the Sponsor, Priveterra's officers and directors, or its or their permitted transferees, the Private Placement Warrants will be redeemable by the Issuer and exercisable by the holders on the same basis as the public warrants; and (v) the Private Placement Warrants (including shares of Class A common stock issuable upon exercise of the private placement warrants) are entitled to registration rights."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As described in the Issuer's Registration Statement on Form S-1 (File No. 333-252310) filed with the Securities and Exchange Commission on January 21, 2021, the Private Placement Warrants are identical to the warrants sold in connection with the Issuer's IPO, except that (i) the Private Placement Warrants (including shares of Class A common stock issuable upon exercise of the private placement warrants) will not be transferable, assignable or salable until 30 days after the completion of the Initial Business Combination (except, among other limited exceptions, to Priveterra's officers and directors, the Sponsor, or any of its or their respective permitted transferees);"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(ii) the Private Placement Warrants will not be redeemable by the Issuer so long as they are held by the Sponsor, Priveterra's officers or directors, or its or their respective permitted transferees (except as set forth in the warrant agreement), (iii) the Private Placement Warrants may be exercised by the Sponsor, Priveterra's officers and directors, or its or their respective permitted transferees on a cashless basis, (iv) if the private placement warrants are held by holders other than the Sponsor, Priveterra's officers and directors, or its or their permitted transferees, the Private Placement Warrants will be redeemable by the Issuer and exercisable by the holders on the same basis as the public warrants; and (v) the Private Placement Warrants (including shares of Class A common stock issuable upon exercise of the private placement warrants) are entitled to registration rights."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"As described in the Issuer's Registration Statement on Form S-1 (File No. 333-252310) filed with the Securities and Exchange Commission on January 21, 2021, the Private Placement Warrants are identical to the warrants sold in connection with the Issuer's IPO, except that (i) the Private Placement Warrants (including shares of Class A common stock issuable upon exercise of the private placement warrants) will not be transferable, assignable or salable until 30 days after the completion of the Initial Business Combination (except, among other limited exceptions, to Priveterra's officers and directors, the Sponsor, or any of its or their respective permitted transferees);"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"(ii) the Private Placement Warrants will not be redeemable by the Issuer so long as they are held by the Sponsor, Priveterra's officers or directors, or its or their respective permitted transferees (except as set forth in the warrant agreement), (iii) the Private Placement Warrants may be exercised by the Sponsor, Priveterra's officers and directors, or its or their respective permitted transferees on a cashless basis, (iv) if the private placement warrants are held by holders other than the Sponsor, Priveterra's officers and directors, or its or their permitted transferees, the Private Placement Warrants will be redeemable by the Issuer and exercisable by the holders on the same basis as the public warrants; and (v) the Private Placement Warrants (including shares of Class A common stock issuable upon exercise of the private placement warrants) are entitled to registration rights."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5280000},"source":{"system":"sec-edgar","filing":"0000950103-23-010810","document":"dp197251_4-psllc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1138646/000095010323010810/dp197251_4-psllc.xml","form_type":"4"}},{"id":1822958,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":111134,"kind":"organization","name":"Priveterra Sponsor, LLC","position":1,"cik":"0001843128","reported_name":"Priveterra Sponsor, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111135,"kind":"person","name":"Grodnensky Oleg","position":2,"cik":"0001843167","reported_name":"Grodnensky Oleg","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36462,"kind":"person","name":"PALMISANO ROBERT J","position":3,"cik":"0001138646","reported_name":"PALMISANO ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":65622,"kind":"person","name":"Malik Vikram","position":4,"cik":"0001730123","reported_name":"Malik Vikram","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Common Stock","published_at":"2023-07-26T21:06:50.000Z","date":"2023-07-21","kind":"exercise","planned":false,"acquired":false,"shares":6900000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Priveterra Acquisition Corp. (\"Priveterra\") Class B common stock were cancelled and, in exchange, the holder(s) thereof was entitled to receive Class A common stock of the Issuer on a one-for-one basis upon the consummation of the Issuer's initial business combination on July 21, 2023 pursuant to that certain Business Combination Agreement (the \"BCA\"), dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"Old AEON\") (the \"Initial Business Combination\"). 2,070,000 of the shares of Class A common stock of the Issuer held by Priveterra Sponsor, LLC. (the \"Sponsor\") are fully vested."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"1,380,000 of the shares of Class A common stock of the Issuer held by the Sponsor vest based on the achievement of certain pre-established share price targets and the remaining 3,450,000 shares of Class A common stock of the Issuer held by the Sponsor will vest based on the achievement of certain milestones, each as set forth in Amendment No.1 to the Sponsor Support Agreement, dated as of April 27, 2023. Simultaneously with the Issuer's initial public offering (\"IPO\"), the Sponsor acquired 5,213,333 warrants of the Issuer exercisable to purchase one share of Class A common stock of the Issuer at an exercise price of $11.50 per share (the \"Private Placement Warrants\") and Sponsor subsequently acquired 66,667 Private Placement Warrants on June 28, 2021 upon the conversion of an unsecured convertible promissory note issued by the Issuer to the Sponsor on February 15, 2021."},{"field":"shares","element":"transactionShares","label":"F7","text":"The reporting person disposed of all Class B common stock upon the consummation of the Issuer's Initial Business Combination, which were automatically exchanged on a one-for-one basis into Class A common stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Priveterra Acquisition Corp. (\"Priveterra\") Class B common stock were cancelled and, in exchange, the holder(s) thereof was entitled to receive Class A common stock of the Issuer on a one-for-one basis upon the consummation of the Issuer's initial business combination on July 21, 2023 pursuant to that certain Business Combination Agreement (the \"BCA\"), dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"Old AEON\") (the \"Initial Business Combination\"). 2,070,000 of the shares of Class A common stock of the Issuer held by Priveterra Sponsor, LLC. (the \"Sponsor\") are fully vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"1,380,000 of the shares of Class A common stock of the Issuer held by the Sponsor vest based on the achievement of certain pre-established share price targets and the remaining 3,450,000 shares of Class A common stock of the Issuer held by the Sponsor will vest based on the achievement of certain milestones, each as set forth in Amendment No.1 to the Sponsor Support Agreement, dated as of April 27, 2023. Simultaneously with the Issuer's initial public offering (\"IPO\"), the Sponsor acquired 5,213,333 warrants of the Issuer exercisable to purchase one share of Class A common stock of the Issuer at an exercise price of $11.50 per share (the \"Private Placement Warrants\") and Sponsor subsequently acquired 66,667 Private Placement Warrants on June 28, 2021 upon the conversion of an unsecured convertible promissory note issued by the Issuer to the Sponsor on February 15, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Priveterra Acquisition Corp. (\"Priveterra\") Class B common stock were cancelled and, in exchange, the holder(s) thereof was entitled to receive Class A common stock of the Issuer on a one-for-one basis upon the consummation of the Issuer's initial business combination on July 21, 2023 pursuant to that certain Business Combination Agreement (the \"BCA\"), dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"Old AEON\") (the \"Initial Business Combination\"). 2,070,000 of the shares of Class A common stock of the Issuer held by Priveterra Sponsor, LLC. (the \"Sponsor\") are fully vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1,380,000 of the shares of Class A common stock of the Issuer held by the Sponsor vest based on the achievement of certain pre-established share price targets and the remaining 3,450,000 shares of Class A common stock of the Issuer held by the Sponsor will vest based on the achievement of certain milestones, each as set forth in Amendment No.1 to the Sponsor Support Agreement, dated as of April 27, 2023. Simultaneously with the Issuer's initial public offering (\"IPO\"), the Sponsor acquired 5,213,333 warrants of the Issuer exercisable to purchase one share of Class A common stock of the Issuer at an exercise price of $11.50 per share (the \"Private Placement Warrants\") and Sponsor subsequently acquired 66,667 Private Placement Warrants on June 28, 2021 upon the conversion of an unsecured convertible promissory note issued by the Issuer to the Sponsor on February 15, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Priveterra Acquisition Corp. (\"Priveterra\") Class B common stock were cancelled and, in exchange, the holder(s) thereof was entitled to receive Class A common stock of the Issuer on a one-for-one basis upon the consummation of the Issuer's initial business combination on July 21, 2023 pursuant to that certain Business Combination Agreement (the \"BCA\"), dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"Old AEON\") (the \"Initial Business Combination\"). 2,070,000 of the shares of Class A common stock of the Issuer held by Priveterra Sponsor, LLC. (the \"Sponsor\") are fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"1,380,000 of the shares of Class A common stock of the Issuer held by the Sponsor vest based on the achievement of certain pre-established share price targets and the remaining 3,450,000 shares of Class A common stock of the Issuer held by the Sponsor will vest based on the achievement of certain milestones, each as set forth in Amendment No.1 to the Sponsor Support Agreement, dated as of April 27, 2023. Simultaneously with the Issuer's initial public offering (\"IPO\"), the Sponsor acquired 5,213,333 warrants of the Issuer exercisable to purchase one share of Class A common stock of the Issuer at an exercise price of $11.50 per share (the \"Private Placement Warrants\") and Sponsor subsequently acquired 66,667 Private Placement Warrants on June 28, 2021 upon the conversion of an unsecured convertible promissory note issued by the Issuer to the Sponsor on February 15, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"The Sponsor is the record holder of the securities reported herein. Messrs Grodnensky, Palmisano, and Malik are the managers of the Sponsor and share voting and investment discretion with respect to the securities held of record by the Sponsor."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6900000},"source":{"system":"sec-edgar","filing":"0000950103-23-010810","document":"dp197251_4-psllc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1138646/000095010323010810/dp197251_4-psllc.xml","form_type":"4"}},{"id":1822957,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":111134,"kind":"organization","name":"Priveterra Sponsor, LLC","position":1,"cik":"0001843128","reported_name":"Priveterra Sponsor, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111135,"kind":"person","name":"Grodnensky Oleg","position":2,"cik":"0001843167","reported_name":"Grodnensky Oleg","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36462,"kind":"person","name":"PALMISANO ROBERT J","position":3,"cik":"0001138646","reported_name":"PALMISANO ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":65622,"kind":"person","name":"Malik Vikram","position":4,"cik":"0001730123","reported_name":"Malik Vikram","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2023-07-26T21:06:50.000Z","date":"2023-07-21","kind":"exercise","planned":false,"acquired":true,"shares":89163,"ownership":{"direct":false,"nature":"Held by Vikram Malik"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Priveterra Acquisition Corp. (\"Priveterra\") Class B common stock were cancelled and, in exchange, the holder(s) thereof was entitled to receive Class A common stock of the Issuer on a one-for-one basis upon the consummation of the Issuer's initial business combination on July 21, 2023 pursuant to that certain Business Combination Agreement (the \"BCA\"), dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"Old AEON\") (the \"Initial Business Combination\"). 2,070,000 of the shares of Class A common stock of the Issuer held by Priveterra Sponsor, LLC. (the \"Sponsor\") are fully vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"1,380,000 of the shares of Class A common stock of the Issuer held by the Sponsor vest based on the achievement of certain pre-established share price targets and the remaining 3,450,000 shares of Class A common stock of the Issuer held by the Sponsor will vest based on the achievement of certain milestones, each as set forth in Amendment No.1 to the Sponsor Support Agreement, dated as of April 27, 2023. Simultaneously with the Issuer's initial public offering (\"IPO\"), the Sponsor acquired 5,213,333 warrants of the Issuer exercisable to purchase one share of Class A common stock of the Issuer at an exercise price of $11.50 per share (the \"Private Placement Warrants\") and Sponsor subsequently acquired 66,667 Private Placement Warrants on June 28, 2021 upon the conversion of an unsecured convertible promissory note issued by the Issuer to the Sponsor on February 15, 2021."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"These securities, which were acquired upon the closing of the Initial Business Combination pursuant to the terms of the BCA as a result of the cancellation of the shares of Old AEON (\"Old AEON Common Stock\") held by Mr. Malik and Sabina Taneja and the automatic conversion of such shares into 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer, are held directly by Mr. Malik, a manager of the Sponsor, and Ms. Taneja. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein."}],"balance_after":6989163,"source":{"system":"sec-edgar","filing":"0000950103-23-010810","document":"dp197251_4-psllc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1138646/000095010323010810/dp197251_4-psllc.xml","form_type":"4"}},{"id":1822956,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":111134,"kind":"organization","name":"Priveterra Sponsor, LLC","position":1,"cik":"0001843128","reported_name":"Priveterra Sponsor, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111135,"kind":"person","name":"Grodnensky Oleg","position":2,"cik":"0001843167","reported_name":"Grodnensky Oleg","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36462,"kind":"person","name":"PALMISANO ROBERT J","position":3,"cik":"0001138646","reported_name":"PALMISANO ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":65622,"kind":"person","name":"Malik Vikram","position":4,"cik":"0001730123","reported_name":"Malik Vikram","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2023-07-26T21:06:50.000Z","date":"2023-07-21","kind":"exercise","planned":false,"acquired":true,"shares":6900000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Priveterra Acquisition Corp. (\"Priveterra\") Class B common stock were cancelled and, in exchange, the holder(s) thereof was entitled to receive Class A common stock of the Issuer on a one-for-one basis upon the consummation of the Issuer's initial business combination on July 21, 2023 pursuant to that certain Business Combination Agreement (the \"BCA\"), dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"Old AEON\") (the \"Initial Business Combination\"). 2,070,000 of the shares of Class A common stock of the Issuer held by Priveterra Sponsor, LLC. (the \"Sponsor\") are fully vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"1,380,000 of the shares of Class A common stock of the Issuer held by the Sponsor vest based on the achievement of certain pre-established share price targets and the remaining 3,450,000 shares of Class A common stock of the Issuer held by the Sponsor will vest based on the achievement of certain milestones, each as set forth in Amendment No.1 to the Sponsor Support Agreement, dated as of April 27, 2023. Simultaneously with the Issuer's initial public offering (\"IPO\"), the Sponsor acquired 5,213,333 warrants of the Issuer exercisable to purchase one share of Class A common stock of the Issuer at an exercise price of $11.50 per share (the \"Private Placement Warrants\") and Sponsor subsequently acquired 66,667 Private Placement Warrants on June 28, 2021 upon the conversion of an unsecured convertible promissory note issued by the Issuer to the Sponsor on February 15, 2021."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"As described in the Issuer's Registration Statement on Form S-1 (File No. 333-252310) filed with the Securities and Exchange Commission on January 21, 2021, the Private Placement Warrants are identical to the warrants sold in connection with the Issuer's IPO, except that (i) the Private Placement Warrants (including shares of Class A common stock issuable upon exercise of the private placement warrants) will not be transferable, assignable or salable until 30 days after the completion of the Initial Business Combination (except, among other limited exceptions, to Priveterra's officers and directors, the Sponsor, or any of its or their respective permitted transferees);"}],"balance_after":6900000,"source":{"system":"sec-edgar","filing":"0000950103-23-010810","document":"dp197251_4-psllc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138646/000095010323010810/dp197251_4-psllc.xml","form_type":"4"}},{"id":1823915,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62488,"kind":"person","name":"Wilson Alexander Blair","position":1,"cik":"0001979602","reported_name":"Wilson Alexander Blair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO and Corporate Secretary"}}],"security":"Restricted Stock Units","published_at":"2023-07-25T01:10:44.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":81428,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Represents an award of RSUs on April 26, 2023, which vests in four yearly installments from April 26, 2023, subject to the reporting person's continued service through the applicable vesting date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F6","text":"At the Effective Time, each outstanding award of restricted stock unit (\"RSU\") representing the contingent right to receive shares of AEON common stock (each an \"AEON RSU\") was automatically cancelled and converted into an RSU representing the contingent right to receive a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON RSU multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F7","text":"Represents an award of RSUs on April 26, 2023, which vests in four yearly installments from April 26, 2023, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents an award of RSUs on April 26, 2023, which vests in four yearly installments from April 26, 2023, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Represents an award of RSUs on April 26, 2023, which vests in four yearly installments from April 26, 2023, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":81428,"derivative":{"underlying":"Common Stock","underlying_shares":81428},"source":{"system":"sec-edgar","filing":"0001104659-23-083570","document":"tm2321918-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465923083570/tm2321918-12_4seq1.xml","form_type":"4"}},{"id":1823914,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62488,"kind":"person","name":"Wilson Alexander Blair","position":1,"cik":"0001979602","reported_name":"Wilson Alexander Blair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO and Corporate Secretary"}}],"security":"Stock Option","published_at":"2023-07-25T01:10:44.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":106609,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F5","text":"Represents an award of stock options on March 9, 2022, which vests in four yearly installments from March 9, 2022, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents an award of stock options on March 9, 2022, which vests in four yearly installments from March 9, 2022, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":106609,"derivative":{"exercise_price":10,"expiration_date":"2032-03-09","underlying":"Common Stock","underlying_shares":106609},"source":{"system":"sec-edgar","filing":"0001104659-23-083570","document":"tm2321918-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465923083570/tm2321918-12_4seq1.xml","form_type":"4"}},{"id":1823913,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62488,"kind":"person","name":"Wilson Alexander Blair","position":1,"cik":"0001979602","reported_name":"Wilson Alexander Blair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO and Corporate Secretary"}}],"security":"Stock Option","published_at":"2023-07-25T01:10:44.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":12656,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents an award of stock options on October 20, 2021, which vests in four yearly installments from October 20, 2021, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents an award of stock options on October 20, 2021, which vests in four yearly installments from October 20, 2021, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":12656,"derivative":{"exercise_price":10,"expiration_date":"2031-10-20","underlying":"Common Stock","underlying_shares":12656},"source":{"system":"sec-edgar","filing":"0001104659-23-083570","document":"tm2321918-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465923083570/tm2321918-12_4seq1.xml","form_type":"4"}},{"id":1823912,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":62488,"kind":"person","name":"Wilson Alexander Blair","position":1,"cik":"0001979602","reported_name":"Wilson Alexander Blair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO and Corporate Secretary"}}],"security":"Stock Option","published_at":"2023-07-25T01:10:44.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":77647,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents an award of stock options on August 23, 2021, which vests in four yearly installments from August 9, 2021, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents an award of stock options on August 23, 2021, which vests in four yearly installments from August 9, 2021, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":77647,"derivative":{"exercise_price":10,"expiration_date":"2031-08-23","underlying":"Common Stock","underlying_shares":77647},"source":{"system":"sec-edgar","filing":"0001104659-23-083570","document":"tm2321918-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465923083570/tm2321918-12_4seq1.xml","form_type":"4"}},{"id":1824068,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36264,"kind":"person","name":"Carter Eric G","position":1,"cik":"0001387660","reported_name":"Carter Eric G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-07-25T01:09:47.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":11802,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents an award of stock options on October 5, 2022, which vests in two yearly installments from October 5, 2022, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents an award of stock options on October 5, 2022, which vests in two yearly installments from October 5, 2022, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":11802,"derivative":{"exercise_price":10,"expiration_date":"2032-10-05","underlying":"Common Stock","underlying_shares":11802},"source":{"system":"sec-edgar","filing":"0001104659-23-083568","document":"tm2321918-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1387660/000110465923083568/tm2321918-11_4seq1.xml","form_type":"4"}},{"id":1824067,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36264,"kind":"person","name":"Carter Eric G","position":1,"cik":"0001387660","reported_name":"Carter Eric G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-07-25T01:09:47.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":9007,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents an award of stock options on September 9, 2021, which vests in four yearly installments from March 9, 2021, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents an award of stock options on September 9, 2021, which vests in four yearly installments from March 9, 2021, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":9007,"derivative":{"exercise_price":10,"expiration_date":"2031-09-09","underlying":"Common Stock","underlying_shares":9007},"source":{"system":"sec-edgar","filing":"0001104659-23-083568","document":"tm2321918-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1387660/000110465923083568/tm2321918-11_4seq1.xml","form_type":"4"}},{"id":1824402,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36519,"kind":"person","name":"Forth Marc","position":1,"cik":"0001816988","reported_name":"Forth Marc","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-07-25T01:07:43.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":279855,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"At the Effective Time, each outstanding award of restricted stock unit (\"RSU\") representing the contingent right to receive shares of AEON common stock (each an \"AEON RSU\") was automatically cancelled and converted into an RSU representing the contingent right to receive a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON RSU multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F8","text":"At the Effective Time, each outstanding award of restricted stock unit (\"RSU\") representing the contingent right to receive shares of AEON common stock (each an \"AEON RSU\") was automatically cancelled and converted into an RSU representing the contingent right to receive a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON RSU multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F9","text":"Represents an award of RSUs on April 26, 2023, which vests in four yearly installments from April 26, 2023, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Represents an award of RSUs on April 26, 2023, which vests in four yearly installments from April 26, 2023, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Represents an award of RSUs on April 26, 2023, which vests in four yearly installments from April 26, 2023, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":279855,"derivative":{"underlying":"Common Stock","underlying_shares":279855},"source":{"system":"sec-edgar","filing":"0001104659-23-083566","document":"tm2321918-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1816988/000110465923083566/tm2321918-9_4seq1.xml","form_type":"4"}},{"id":1824401,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36519,"kind":"person","name":"Forth Marc","position":1,"cik":"0001816988","reported_name":"Forth Marc","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-07-25T01:07:43.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":194118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F7","text":"Represents an award of stock options on March 9, 2022, which vests in four yearly installments from March 9, 2022, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents an award of stock options on March 9, 2022, which vests in four yearly installments from March 9, 2022, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":194118,"derivative":{"exercise_price":10,"expiration_date":"2032-03-09","underlying":"Common Stock","underlying_shares":194118},"source":{"system":"sec-edgar","filing":"0001104659-23-083566","document":"tm2321918-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1816988/000110465923083566/tm2321918-9_4seq1.xml","form_type":"4"}},{"id":1824400,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36519,"kind":"person","name":"Forth Marc","position":1,"cik":"0001816988","reported_name":"Forth Marc","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-07-25T01:07:43.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":381480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F6","text":"Represents an award of stock options on March 9, 2022, which vests in four yearly installments from March 9, 2022, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Represents an award of stock options on March 9, 2022, which vests in four yearly installments from March 9, 2022, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":381480,"derivative":{"exercise_price":10,"expiration_date":"2032-03-09","underlying":"Common Stock","underlying_shares":381480},"source":{"system":"sec-edgar","filing":"0001104659-23-083566","document":"tm2321918-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1816988/000110465923083566/tm2321918-9_4seq1.xml","form_type":"4"}},{"id":1824399,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36519,"kind":"person","name":"Forth Marc","position":1,"cik":"0001816988","reported_name":"Forth Marc","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-07-25T01:07:43.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":291332,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F5","text":"Represents an award of stock options on September 9, 2021, which vests in four yearly installments from March 5, 2021, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents an award of stock options on September 9, 2021, which vests in four yearly installments from March 5, 2021, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":291332,"derivative":{"exercise_price":10,"expiration_date":"2031-09-09","underlying":"Common Stock","underlying_shares":291332},"source":{"system":"sec-edgar","filing":"0001104659-23-083566","document":"tm2321918-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816988/000110465923083566/tm2321918-9_4seq1.xml","form_type":"4"}},{"id":1824398,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36519,"kind":"person","name":"Forth Marc","position":1,"cik":"0001816988","reported_name":"Forth Marc","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-07-25T01:07:43.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":324021,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents an award of stock options on August 5, 2020, which vests in four yearly installments from July 1, 2020, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents an award of stock options on August 5, 2020, which vests in four yearly installments from July 1, 2020, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":324021,"derivative":{"exercise_price":10,"expiration_date":"2030-08-05","underlying":"Common Stock","underlying_shares":324021},"source":{"system":"sec-edgar","filing":"0001104659-23-083566","document":"tm2321918-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816988/000110465923083566/tm2321918-9_4seq1.xml","form_type":"4"}},{"id":1824397,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36519,"kind":"person","name":"Forth Marc","position":1,"cik":"0001816988","reported_name":"Forth Marc","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2023-07-25T01:07:43.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":970588,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents an award of stock options on November 20, 2019, which vests in four yearly installments from June 11, 2019, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents an award of stock options on November 20, 2019, which vests in four yearly installments from June 11, 2019, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":970588,"derivative":{"exercise_price":10,"expiration_date":"2029-11-20","underlying":"Common Stock","underlying_shares":970588},"source":{"system":"sec-edgar","filing":"0001104659-23-083566","document":"tm2321918-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816988/000110465923083566/tm2321918-9_4seq1.xml","form_type":"4"}},{"id":1824079,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36267,"kind":"person","name":"FISCHER JOST","position":1,"cik":"0001366841","reported_name":"FISCHER JOST","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-07-25T01:06:39.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":35189,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"At the Effective Time, each outstanding award of restricted stock unit (\"RSU\") representing the contingent right to receive shares of AEON common stock (each an \"AEON RSU\") was automatically cancelled and converted into an RSU representing the contingent right to receive a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON RSU multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023 (the \"Business Combination Agreement\"), by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F6","text":"At the Effective Time, each outstanding award of restricted stock unit (\"RSU\") representing the contingent right to receive shares of AEON common stock (each an \"AEON RSU\") was automatically cancelled and converted into an RSU representing the contingent right to receive a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON RSU multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F9","text":"Represents an award of RSUs on April 26, 2023, which vests as follows: (1) 6.25% upon the achievement of the first earnout in connection with the Business Combination Agreement; (2) 25% upon the achievement of the second earnout in connection with the Business Combination Agreement; (3) 25% upon the achievement of the third earnout in connection with the Business Combination Agreement; and (4) 43.75% upon the achievement of the fourth earnout in connection with the Business Combination Agreement, subject to the reporting person's continued service through the applicable vesting condition."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023 (the \"Business Combination Agreement\"), by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Represents an award of RSUs on April 26, 2023, which vests as follows: (1) 6.25% upon the achievement of the first earnout in connection with the Business Combination Agreement; (2) 25% upon the achievement of the second earnout in connection with the Business Combination Agreement; (3) 25% upon the achievement of the third earnout in connection with the Business Combination Agreement; and (4) 43.75% upon the achievement of the fourth earnout in connection with the Business Combination Agreement, subject to the reporting person's continued service through the applicable vesting condition."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Represents an award of RSUs on April 26, 2023, which vests as follows: (1) 6.25% upon the achievement of the first earnout in connection with the Business Combination Agreement; (2) 25% upon the achievement of the second earnout in connection with the Business Combination Agreement; (3) 25% upon the achievement of the third earnout in connection with the Business Combination Agreement; and (4) 43.75% upon the achievement of the fourth earnout in connection with the Business Combination Agreement, subject to the reporting person's continued service through the applicable vesting condition."}],"balance_after":35189,"derivative":{"underlying":"Common Stock","underlying_shares":35189},"source":{"system":"sec-edgar","filing":"0001104659-23-083565","document":"tm2321918-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1366841/000110465923083565/tm2321918-8_4seq1.xml","form_type":"4"}},{"id":1824078,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36267,"kind":"person","name":"FISCHER JOST","position":1,"cik":"0001366841","reported_name":"FISCHER JOST","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-07-25T01:06:39.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":6289,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"At the Effective Time, each outstanding award of restricted stock unit (\"RSU\") representing the contingent right to receive shares of AEON common stock (each an \"AEON RSU\") was automatically cancelled and converted into an RSU representing the contingent right to receive a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON RSU multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023 (the \"Business Combination Agreement\"), by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F6","text":"At the Effective Time, each outstanding award of restricted stock unit (\"RSU\") representing the contingent right to receive shares of AEON common stock (each an \"AEON RSU\") was automatically cancelled and converted into an RSU representing the contingent right to receive a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON RSU multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F8","text":"Represents an award of RSUs on April 26, 2023, which vests in one installment on April 26, 2024, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023 (the \"Business Combination Agreement\"), by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Represents an award of RSUs on April 26, 2023, which vests in one installment on April 26, 2024, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Represents an award of RSUs on April 26, 2023, which vests in one installment on April 26, 2024, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":6289,"derivative":{"underlying":"Common Stock","underlying_shares":6289},"source":{"system":"sec-edgar","filing":"0001104659-23-083565","document":"tm2321918-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1366841/000110465923083565/tm2321918-8_4seq1.xml","form_type":"4"}},{"id":1824077,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36267,"kind":"person","name":"FISCHER JOST","position":1,"cik":"0001366841","reported_name":"FISCHER JOST","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-07-25T01:06:39.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":19286,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"At the Effective Time, each outstanding award of restricted stock unit (\"RSU\") representing the contingent right to receive shares of AEON common stock (each an \"AEON RSU\") was automatically cancelled and converted into an RSU representing the contingent right to receive a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON RSU multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023 (the \"Business Combination Agreement\"), by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F6","text":"At the Effective Time, each outstanding award of restricted stock unit (\"RSU\") representing the contingent right to receive shares of AEON common stock (each an \"AEON RSU\") was automatically cancelled and converted into an RSU representing the contingent right to receive a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON RSU multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F7","text":"Represents an award of RSUs on April 26, 2023, which vests in one installment on April 26, 2024, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023 (the \"Business Combination Agreement\"), by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents an award of RSUs on April 26, 2023, which vests in one installment on April 26, 2024, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Represents an award of RSUs on April 26, 2023, which vests in one installment on April 26, 2024, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":19286,"derivative":{"underlying":"Common Stock","underlying_shares":19286},"source":{"system":"sec-edgar","filing":"0001104659-23-083565","document":"tm2321918-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1366841/000110465923083565/tm2321918-8_4seq1.xml","form_type":"4"}},{"id":1824076,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36267,"kind":"person","name":"FISCHER JOST","position":1,"cik":"0001366841","reported_name":"FISCHER JOST","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-07-25T01:06:39.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":21198,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023 (the \"Business Combination Agreement\"), by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F5","text":"Represents an award of stock options on March 9, 2022, which vests in 12 monthly installments from March 9, 2022, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023 (the \"Business Combination Agreement\"), by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents an award of stock options on March 9, 2022, which vests in 12 monthly installments from March 9, 2022, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":12198,"derivative":{"exercise_price":10,"expiration_date":"2032-03-09","underlying":"Common Stock","underlying_shares":21198},"source":{"system":"sec-edgar","filing":"0001104659-23-083565","document":"tm2321918-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1366841/000110465923083565/tm2321918-8_4seq1.xml","form_type":"4"}},{"id":1824075,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36267,"kind":"person","name":"FISCHER JOST","position":1,"cik":"0001366841","reported_name":"FISCHER JOST","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-07-25T01:06:39.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":19800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023 (the \"Business Combination Agreement\"), by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents an award of stock options on March 5, 2021, which vests in 12 monthly installments from March 5, 2021, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023 (the \"Business Combination Agreement\"), by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents an award of stock options on March 5, 2021, which vests in 12 monthly installments from March 5, 2021, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":19800,"derivative":{"exercise_price":10,"expiration_date":"2031-03-05","underlying":"Common Stock","underlying_shares":19800},"source":{"system":"sec-edgar","filing":"0001104659-23-083565","document":"tm2321918-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1366841/000110465923083565/tm2321918-8_4seq1.xml","form_type":"4"}},{"id":1824074,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36267,"kind":"person","name":"FISCHER JOST","position":1,"cik":"0001366841","reported_name":"FISCHER JOST","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-07-25T01:06:39.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":21974,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023 (the \"Business Combination Agreement\"), by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents an award of stock options on August 5, 2020, which vests in 12 monthly installments from March 4, 2020, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023 (the \"Business Combination Agreement\"), by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents an award of stock options on August 5, 2020, which vests in 12 monthly installments from March 4, 2020, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":21974,"derivative":{"exercise_price":10,"expiration_date":"2030-08-05","underlying":"Common Stock","underlying_shares":21974},"source":{"system":"sec-edgar","filing":"0001104659-23-083565","document":"tm2321918-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1366841/000110465923083565/tm2321918-8_4seq1.xml","form_type":"4"}},{"id":1824073,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36267,"kind":"person","name":"FISCHER JOST","position":1,"cik":"0001366841","reported_name":"FISCHER JOST","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-07-25T01:06:39.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":2353,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023 (the \"Business Combination Agreement\"), by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."}],"balance_after":2353,"source":{"system":"sec-edgar","filing":"0001104659-23-083565","document":"tm2321918-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1366841/000110465923083565/tm2321918-8_4seq1.xml","form_type":"4"}},{"id":1824072,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":36267,"kind":"person","name":"FISCHER JOST","position":1,"cik":"0001366841","reported_name":"FISCHER JOST","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-07-25T01:06:39.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":13274,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023 (the \"Business Combination Agreement\"), by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."}],"balance_after":13274,"source":{"system":"sec-edgar","filing":"0001104659-23-083565","document":"tm2321918-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1366841/000110465923083565/tm2321918-8_4seq1.xml","form_type":"4"}},{"id":1824287,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":61532,"kind":"person","name":"Oh Chad","position":1,"cik":"0001882166","reported_name":"Oh Chad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2023-07-24T21:08:48.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":100428,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Represents an award of RSUs on April 26, 2023, which vests in four yearly installments from April 26, 2023, subject to the reporting person's continued service through the applicable vesting date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F5","text":"At the Effective Time, each outstanding award of restricted stock unit (\"RSU\") representing the contingent right to receive shares of AEON common stock (each an \"AEON RSU\") was automatically cancelled and converted into an RSU representing the contingent right to receive a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON RSU multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F6","text":"Represents an award of RSUs on April 26, 2023, which vests in four yearly installments from April 26, 2023, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Represents an award of RSUs on April 26, 2023, which vests in four yearly installments from April 26, 2023, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Represents an award of RSUs on April 26, 2023, which vests in four yearly installments from April 26, 2023, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":100428,"derivative":{"underlying":"Common Stock","underlying_shares":100428},"source":{"system":"sec-edgar","filing":"0001104659-23-083567","document":"tm2321918-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1882166/000110465923083567/tm2321918-10_4seq1.xml","form_type":"4"}},{"id":1824286,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":61532,"kind":"person","name":"Oh Chad","position":1,"cik":"0001882166","reported_name":"Oh Chad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2023-07-24T21:08:48.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":115151,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents an award of stock options on March 9, 2022, which vests in four yearly installments from March 9, 2022, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents an award of stock options on March 9, 2022, which vests in four yearly installments from March 9, 2022, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":115151,"derivative":{"exercise_price":10,"expiration_date":"2032-03-09","underlying":"Common Stock","underlying_shares":115151},"source":{"system":"sec-edgar","filing":"0001104659-23-083567","document":"tm2321918-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1882166/000110465923083567/tm2321918-10_4seq1.xml","form_type":"4"}},{"id":1824285,"issuer":{"id":7859,"kind":"organization","name":"AEON Biopharma, Inc."},"owners":[{"id":61532,"kind":"person","name":"Oh Chad","position":1,"cik":"0001882166","reported_name":"Oh Chad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2023-07-24T21:08:48.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":145588,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an \"AEON Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents an award of stock options on August 23, 2021, which vests in four yearly installments from May 31, 2021, subject to the reporting person's continued service through the applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. (\"Merger Sub\") and AEON Biopharma, Inc. (\"AEON\"), upon consummation of the transactions contemplated thereby (the \"Effective Time\"), each issued and outstanding share of common stock of AEON (\"AEON common stock\") was automatically cancelled and converted into approximately 2.328 (the \"Exchange Ratio\") shares of Class A common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents an award of stock options on August 23, 2021, which vests in four yearly installments from May 31, 2021, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":145588,"derivative":{"exercise_price":10,"expiration_date":"2031-08-23","underlying":"Common Stock","underlying_shares":145588},"source":{"system":"sec-edgar","filing":"0001104659-23-083567","document":"tm2321918-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1882166/000110465923083567/tm2321918-10_4seq1.xml","form_type":"4"}}]}